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INTRODUCTION 
 
1.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)  
Human immunodeficiency virus (HIV) is a retrovirus belonging to the 
lentivirus genus. There are two known types of HIV: HIV-1 and HIV-2, of which 
HIV-1 is more prevalent in India. There are three distinct groups of HIV-1: Major 
(M), Novel (N), Outliers (O) and possibly a group (P). The group M strain can be 
further divided into different subtypes (A, B, C, D, E, F, G, H, J, and K). Subtype C is 
the most commonly prevalent subtype in India [1].  The HIV genome consists of three 
major genes (gag, pol, env) that encode for structural proteins; three viral enzymes 
(reverse transcriptase - RT, protease, integrase) and six minor genes in two sets 
distinguished by coding for regulatory (tat, rev) or accessory (nef, vif, vpr, vpu) 
proteins. 
 
1.1.1 Transmission and Pathogenesis of HIV  
There are three main modes of HIV transmission: i) through unprotected 
sexual intercourse with an HIV-infected individual, ii) contact with HIV-infected 
blood through the blood itself, blood products, transplanted organs, or the use of 
inadequately sterilized needles syringes and iii) Mother-to-child transmission during 
pregnancy, childbirth, or breastfeeding.  
As HIV enters the bloodstream via mucous membranes, macrophages and 
dendritic cells on the surface of the mucous membranes bind the virus and carry it to 
the lymph nodes, which contain high concentrations of Helper T-cells (CD4+ T-cells). 
The immune system initiates anti-HIV antibody and cytotoxic T-cell production that 
may take approximately one to three months to have measurable antibody quantities. 
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Figure 1: Life Cycle of Human Immunodeficiency Virus 
 
 
HIV attaches to the CD4 molecule on the surface of T‐helper (CD4+) lymphocytes 
using the viral envelope protein gp120. After attachment, the virion uncoats, and the 
viral genome is injected into the cytoplasm. Within the cytoplasm, the viral enzyme 
reverse transcriptase transcribes HIV viral RNA into the host’s DNA. The proviral 
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DNA product then moves to the cell nucleus and is integrated into the host cell 
genome with the help of the viral enzyme, integrase. Viral RNA and viral proteins are 
assembled and processed with the help of the viral enzyme protease. The virions then 
bud off at the cell surface and pass into the extracellular environment. This process 
results in massive viremia and progressive immunosuppression due to depletion of 
CD4 cells with time.  Initially the body replaces the lost CD4 cells but over time the 
rate of destruction of CD4 cells outpaces replacement and the CD4 count falls as the 
viral load increases. The base life cycle of HIV is shown in Figure 1.       
 
1.1.2 Stages of HIV infection 
(i) Seroconversion: Occurs about 3-6 weeks after exposure to HIV and in 
around 20% of individuals this is characterized by fever, rash, sore throat, and 
lymphadenopathy. 
(ii) Asymptomatic Phase: The patient becomes asymptomatic following the 
seroconversion stage. The asymptomatic period can last for about 8 to10 years. 
During this period, antibodies are detectable in the blood of the HIV infected 
individuals, and the host immune system is able to control the damage to some extent.       
(iii) Symptomatic Phase: Eventually the immune system is not able to 
maintain pace with the damage caused by HIV, at which point the patient becomes 
symptomatic and develops recurrent infections. Later, there is profound compromise 
of the immune system, leading to the state of immunodeficiency called Acquired 
Immunodeficiency Syndrome (AIDS), and the patient develops AIDS-defining 
illnesses. This syndrome in turn leads to an increased risk of infectious morbidity and 
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mortality among HIV infected individuals [2]. In the absence of antiretroviral 
treatment, the development to AIDS is certain in HIV-infected individuals.               
 
 
1.2 ANTIRETROVIRAL DRUGS AND MECHANISM OF ACTION  
Antiretroviral agents must be used in combination for effective treatment of 
HIV infection. There are seven classes of antiretroviral agents approved by the United 
States Food and Drug Administration (FDA) which currently consists of 22 individual 
drugs.  The classes are:  
1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
2. Nucleotide Reverse Transcriptase Inhibitors (NtRTI) 
3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
4. Protease Inhibitors (PIs) 
5. Fusion Inhibitors 
6. CCR5 Antagonists 
7. Integrase Inhibitors 
The most commonly used classes of anti-retroviral drugs in India are 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nucleotide Reverse 
Transcriptase Inhibitors (NtRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs) and Protease Inhibitors (PIs), that are further described below:  
 
1.2.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
These were the first class of antiretroviral drugs to be developed. NRTIs must 
undergo intracellular triphosphorylation in order to become active against HIV. 
NRTI’s compete with host nucleotides to serve as the substrate for reverse 
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transcriptase chain elongation. The absence of a 3-OH group on the sugar moiety 
prevents the addition of nucleotide resulting in chain termination. Consequently viral 
DNA chain elongation is aborted and viral replication ceases.  
The most commonly used NRTIs include Stavudine, Lamivudine, Zidovudine, 
and Didanosine. Figure 2a shows the incorporation of a nucleoside analogue in a 
drug-sensitive virus resulting in the termination of the viral DNA chain [3]. 
 
1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
These were the second class of antiretrovirals to be developed. NNRTIs inhibit 
the HIV reverse transcriptase by binding to a hydrophobic pocket close to the active 
site thus locking the enzyme’s active site in an inactive conformation (Figure 2b). 
These classes of drugs are potent but are subject to the rapid emergence of resistance. 
Consequently NNRTIs are active against HIV-1 but not active against HIV-2. 
NNRTIs are metabolized by the CYP3A4 isoenzyme of the hepatic cytochrome p450 
system and are either potent inducers or inhibitors of CYP3A4. Hence they have the 
potential for major drug interactions with HIV and non-HIV agents, including 
antimycobacterials. The most commonly used NNRTIs include Nevirapine and 
Efavirenz.  
Figure 2a & 2b show the mechanism of action of NRTI and NNRTI class of 
antiretroviral drugs. 
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Figure 2a: Mechanism of action of NRTIs: NRTIs get incorporated into the virus 
and the DNA chain is terminated from replication 
 
. 
8 
 
Figure 2b: Mechanism of action of NNRTIs: NNRTIs bind to the pocket next to the 
active site of reverse transcriptase and block the polymerization of DNA by reverse 
transcriptase  
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1.2.3 Protease Inhibitors (PIs) 
These are the third class of antiretrovirals to be developed. PI’s inhibit HIV 
protease by binding to its active site and preventing the cleavage of gag and gag-pol 
precursor proteins such that though virions are produced, they are incomplete and 
non-infectious.  PIs are metabolized by the CYP3A4 isoenzyme of the hepatic 
cytochrome p450 system and are inhibitors of CYP3A4 to varying degrees. Therefore 
they also have the potential for major drug interactions with numerous HIV and non-
HIV agents. Ritonavir is one of the most potent CYP3A4 inhibitors known and is 
used to “boost” levels of other PI’s. 
 
1.2.4 Other antiretroviral drugs  
a) Fusion Inhibitors: Fusion Inhibitors prevent entry by binding to 
glycoprotein on the viral envelope. For example, Enfuvirtide, T20 binds to the gp41 
envelope glycoprotein. These are available currently only in injectable form.  
b) CCR5 antagonists : These prevent entry by binding to the chemokine 
coreceptor on the host CD4+ cell. For example, Maraviroc binds to the CCR5 
coreceptor (Although it is active against the CCR5 tropic virus only). 
c) Integrase Inhibitor:  These act by inhibiting the DNA strand transfer into the 
host-cell genome thus preventing viral integration. They are very potent in-vitro and 
in-vivo drugs that work synergistically with all antiretrovirals and have few side 
effects and drug interactions. Raltegravir is an example of this class. Figure 2c shows 
the mechanism of action of all available antiretroviral drugs, including fusion 
inhibitors and integrase inhibitors.  
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Figure 2 C: Mechanism of action of antiretroviral drugs including Fusion and 
Integrase inhibitors 
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The major limitations of currently available antiretroviral drugs include: 
toxicities and adverse effects, emergence of resistance, long-term usage resulting in 
“treatment fatigue”, drug-class cross resistance, drug-to-drug interactions, and 
complexity in dosing, and cost in “resource limited” settings. 
 
1.3 TREATMENT OF HIV DISEASE 
There are two important HIV disease staging and classification systems that 
provide information about the stages of HIV disease and its management:  
a) The Centers for Disease Control and Prevention (CDC) Classification 
System: Assesses the severity of HIV disease based on CD4 cell counts and the 
presence of specific HIV-related conditions.  
b) The World Health Organization (WHO) Clinical Staging and Disease 
Classification System: Classifies HIV disease on the basis of clinical manifestations 
that can be recognized and treated by clinicians in diverse settings including resource-
constrained settings where facilities for CD4 counts are not readily available.  
 
1.3.1 Treatment and Care for HIV infected individuals in India  
The Government of India runs a National ART Programme that provides free 
ART to all HIV-infected children and adults through ART centers spread across the 
country. The key goals of this Programme is to provide long-term ART to eligible 
patients, monitoring and reporting treatment outcomes on a quarterly basis, achieving 
individual drug adherence levels of 95% or more, increasing the life span of patients 
on treatment so that 50% of them are alive 3 years after starting the treatment, and 
ensuring that 50% of patients on ART can return to their previous employment.  
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The National ART Programme of India recommends the use of following 
three types of combination regimens in treatment-naïve individuals: NNRTI-based (1 
NNRTI + 2 NRTI), PI-based (Ritonavir boosted PI + 2 NRTI), and triple NRTI-based 
regimens. Regimen selection should be individualized, taking into consideration a 
number of factors including: comorbidity or conditions such as tuberculosis, liver 
disease, depression or mental illness, cardiovascular disease, potential adherence, 
adverse events and drug-drug interaction. An NNRTI based regimen is recommended 
as the first-line therapy for most ART-naïve HIV infected individuals. NNRTI- based 
regimens are potent, have shown comparable efficacy to ritonavir boosted PI based 
regimens, and are superior to the triple NRTI-based regimen in terms of treatment 
efficacy. The National Programme provides the following combinations for first-line 
regimens: 
i. Stavudine (30 mg) + Lamivudine (150 mg) + Nevirapine (200 mg) 
ii. Zidovudine (300 mg) + Lamivudine (150 mg) + Nevirapine (200 mg) 
iii. Stavudine (30 mg) + Lamivudine (150 mg) + Efavirenz (600 mg) 
iv. Zidovudine (300 mg) + Lamivudine (150 mg) + Efavirenz (600 mg) 
v. Abacavir + Lamivudine (150 mg) + Nevirapine (200 mg) 
vi. Abacavir + Lamivudine (150 mg) + Efavirenz (600 mg) 
Clinical use of two different classes of anti-viral drugs, Nucleoside Reverse 
Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase 
Inhibitors (NNRTIs) have not only improved the clinical course of these patients but 
also has prolonged their live span. The implementation of ART has led to increased 
life expectancies among people living with HIV approaching that of the general 
population. However, drug toxicities and the emergence of drug resistance 
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compromise the efficacy of antiretroviral agents. Long-term use of these anti-viral 
drugs, like any other drug, results in complications and adverse events that may affect 
the patient’s quality of life. 
 
1.4 COMPLICATIONS OF LONG-TERM ANTIRETROVIRAL THERAPY  
Potent antiretroviral therapy has significantly reduced the morbidity and 
mortality associated with HIV and AIDS. Unfortunately the benefits of ART are 
overshadowed by the complications associated with its long-term use - a few of which 
include lactic acidosis, lipodystrophy, dyslipidemia, glucose intolerance, osteopenia, 
osteoporosis, atherosclerosis, and cardiovascular complications [4]. Although ART 
has led to an overall reduction of morbidity and mortality in HIV infected patients, 
changes in lipid profiles have been reported with a significant increase in both 
cardiovascular risk and the risk of developing diabetes mellitus in adults [5]. Loss of 
bone mineral density and vitamin deficiency resulting in bone demineralization has 
been reported in children on ART [6]. The combination of severe malnutrition and 
concurrent micronutrient deficiencies in children initiating ART in resource-limited 
settings may lead to further reductions in bone mineral density in this population [7]. 
With the World Health Organisation recommending early initiation of ART among 
children infected with HIV, children will be exposed to a longer duration of ART 
during their life span than their predecessors with a higher life-time risk for 
developing metabolic complications and cardiovascular morbidities like 
atherosclerosis and arterial wall thickening. 
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1.5 METABOLIC COMPLICATIONS OF ART 
The metabolic complications of ART are well-documented in adults. Use of 
NRTIs - Stavudine, Zidovudine and Didanosine are closely linked to lipodystrophy 
and lactic acidosis [8]. Alterations to the lipid metabolism of HIV-infected adults 
have become increasingly prevalent with the widespread use of antiretroviral therapy 
(ART). The result is that metabolic changes and body fat redistribution have been 
regrouped into an entity called “HIV associated Lipodystrophy Syndrome [9]. The 
three main components of this syndrome are abnormal blood lipid profiles (mostly 
hypercholesterolemia and hypertriglyceridemia), insulin resistance, and body fat 
redistribution. Each of these metabolic abnormalities could affect the long-term 
outcome of HIV infected individuals. Fat redistribution and body shape changes can 
affect the individual psychologically. With body shape changes like, buffalo hump or 
sunken cheeks, thinned out limbs, he or she may start skipping clinic appointments for 
drug collection. This can affect their adherence to antiretroviral drugs and ultimately 
their response to ART as well. Determining abnormal lipid profiles is complicated by 
varying published definitions of hypercholesterolemia and hypertriglyceridemia. The 
guidelines issued by the National Heart, Lung and Blood Institute (NHLBI) Expert 
Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in 
Children and Adolescents were endorsed by the American Academy of Paediatrics 
[10] and are thus considered acceptable for this study. 
 
1.5.1 Lipodystrophy Syndrome in children on ART 
The lipodystrophy Syndrome has been observed in HIV infected children 
treated with ART and may be associated with abnormalities in both lipid regulation 
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(hyperlipidaemia) and glucose metabolism (insulin resistance) [11]. Body fat 
maldistribution is especially problematic in children and adolescents (who are 
generally sensitive to their body image) leading to stigmatization, depression, non-
adherence to treatment and ultimately leading to treatment failure. Lipodystrophy 
Syndrome consists of changes in regional fat distribution manifesting as either 
lipoatrophy (with or without central adiposity) or lipohypertrophy. There are three 
patterns of body fat maldistribution: (1) Lipoatrophy, with decrease in subcutaneous 
fat in the face, limbs and/or buttocks; (2) Lipohypertrophy, with accumulation of fat 
in the upper chest, abdomen, breast, and/or dorsocervical region [12]. These 
symptoms of lipohypertrophy conspicuously manifest as an enlargement of 
dorsocervical fat pad popularly called as “buffalo hump”, axial fat pads, an expansion 
in abdominal girth commonly known as “Crix belly”, thinning of the extremities, and 
subcutaneous loss of fat; (3) A mixed/combined pattern with both lipoatrophy and 
lipohypertrophy. As implied by the variety of descriptions above, children affected 
with Lipodystrophy Syndrome may show different patterns and severity in fat 
maldistributions. 
Lipodystrophy is most likely to develop at the time of puberty. Although some 
studies report higher prevalence of lipodystrophy among females than males, there is 
no consensus on this finding [13]. Lipodystrophy has been noted with higher 
frequency among children with rapid immunologic recovery [14]. Although 
lipoatrophy and lipohypertrophy can occur independent of one another, lipoatrophy is 
more correlated to HIV and constitutes a key component of lipodystrophy [15]. In 
many HIV infected cohorts, lipoatrophy is seen more frequently than lipohypertrophy. 
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Prevalence of Lipodystrophy Syndrome: The prevalence of lipodystrophy in 
children varies by geographic region, depending on the ART regimen used locally 
(either PI-based regimens or Stavudine-containing regimen) and the availability and 
duration of ART. The prevalence of Lipodystrophy Syndrome in HIV-infected 
children has been estimated to range from 18-54% in various studies [16-20]. 
However, there are varying definitions of lipodystrophy syndrome and not much 
consensus about the regular monitoring of lipids in children on ART. This is partly 
due to recognition that the assessment of fat redistribution in HIV-infected children is 
complicated by the normal, dynamic alterations in body composition that occur during 
childhood and adolescence. 
 
1.5.2 Dyslipidaemia in children on ART 
Dyslipidaemias, or abnormal blood lipid levels, are a common component of 
ART-associated lipodystrophy syndrome but can also occur in the absence of 
lipoatrophy or lipohypertrophy [19]. In adults such serum lipid profile changes may 
represent a “normalization” of health because lipoprotein levels during HIV-infection 
and prior to ART initiation are demonstrably lower than normal but rise after 
initiation of ART. In contrast to other lipoproteins, HDL-c levels lower with the onset 
of HIV infection and do not increase after ART is introduced [20]. Low levels of 
high-density lipoprotein cholesterol (HDL-c), low levels of low-density lipoprotein 
cholesterol (LDL-c), and elevated triglycerides have all been associated with HIV in 
adults [21, 22].  
Prevalence of dyslipidaemia: Up to 40% of HIV-infected children are 
reported to develop lipid abnormalities consisting mainly of elevated serum 
triglyceride (TGL) and total cholesterol (TC) levels and low high-density lipoprotein 
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cholesterol (HDL-c) levels [23-25]. Smaller changes in low-density lipoprotein 
cholesterol (LDL-c) have also been noted. Various drugs used in the management of 
HIV infection cause dyslipidaemia. Among the NRTIs, Stavudine is associated with 
increased levels of TC, LDL-c and TGL [25]. All Protease Inhibitors are associated 
with elevated TGL, LDL-c and TC levels [26]. The elevations in serum cholesterol 
levels while on ART are observably similar to those seen in patients heterozygous for 
familial hypercholesterolemia therefore implying a similar risk for premature 
atherosclerotic disease [27].  
Effect of Dyslipidemia: These lipid changes increase the risk of 
cardiovascular disease in HIV patients much as they do in non-HIV-infected adults. It 
is not known how risky these lipid changes are in HIV-infected children and 
adolescents receiving ART, but certainly the young are not immune to the risk of 
early atheroma formation and the development of cardiovascular disease. In adults, 
those with HIV are at heightened risk for cardiovascular morbidity and mortality [28, 
29]. Long-term studies are needed to document the cardiovascular disease burden in 
children with HIV-associated dyslipidaemia, their risk of having cardiovascular 
events in the future, and the effectiveness of interventions to lower the risk of these 
events. 
AIDS-related lipodystrophy syndrome is also associated with carbohydrate 
intolerance, insulin resistance or overt diabetes mellitus. 
 
1.5.3 Insulin resistance in children on ART  
Insulin resistance is characterized by the decreased ability of insulin to 
stimulate the use of glucose by muscles and adipose tissue, leading to increased 
production of pancreatic insulin. A multitude of glucose metabolism disorders have 
18 
 
been associated with HIV infection and ART including impaired glucose tolerance, 
impaired fasting glucose, and type-2 diabetes mellitus (DM). Both insulin resistance 
and impaired insulin secretion have been described as the reason for impaired glucose 
tolerance among HIV infected children [30]. This reduced tolerance increases the risk 
of diabetes mellitus among children receiving ART compared to the uninfected 
control subjects. 
Prevalence of insulin resistance: Impaired glucose tolerance has been 
reported in 8–15% of HIV-infected children [16, 25, 29, 31]. Diabetes mellitus by 
itself further increases the risk of dyslipidaemia and vascular complications, both 
microvascular and macrovascular. Under normal conditions, Protease Inhibitor class 
of drugs are associated with the development of glucose intolerance. However, no 
differences were detected in fasting serum insulin, proinsulin, C-peptide, insulin: 
glucose ratio or Homeostasis Model of Assessment (HOMA-IR) indicators between 
PI-treated and PI-naïve children [32]. High-fasting insulin concentrations have been 
reported consistently among children with lipohypertrophy and inconsistently in 
children with lipoatrophy. Nonetheless, prolonged exposure to high insulin levels may 
increase their risk of type-2 diabetes mellitus. There is limited longitudinal data on the 
incidence of insulin resistance among HIV-infected children on ART though some 
reports have shown an increased prevalence over time [32, 33]. 
 
1.6 PATHOPHYSIOLOGY OF HIV ASSOCIATED LIPODYSTROPHY 
SYNDROME  
The precise mechanisms of Lipodystrophy Syndrome are complex, 
multifactorial and, not well understood. Proposed hypotheses for this include 
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metabolic disorder, mitochondrial and adipocyte cell malfunction, genetic 
polymorphisms etc. [34, 35].  
 
1.7 HIV ASSOCIATED LIPODYSTROPHY SYNDROME IN INDIA (HALS) 
 With the rapid scale-up of antiretroviral therapy, increasing numbers of HIV-
infected Indian children receive antiretroviral therapy and these children experience 
increased longevity with a considerable reduction in HIV-related mortality. Early 
challenges have been met: the standard triple drug combination of two nucleoside 
reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor 
has been reformulated for paediatric use and weight-based dosing guidelines have 
been developed. Generic paediatric formulations are now available through 
government ART centers. However, long-term challenges remain: there is a dearth of 
knowledge about the development of long term metabolic complications in these 
children on first-line ART, particularly in areas where malnutrition may coexist. 
Studies on HIV-infected Indian adults conclude that lipoatrophy is the predominant 
manifestation of lipodystrophy and that the risk factors include age, female sex, and 
duration of therapy [36, 37]. Yet there is a dearth of knowledge on the development of 
long term metabolic complications in Indian children on NRTI (Stavudine / 
Zidovudine) containing first-line ART, particularly in areas where malnutrition may 
co-exist.   
 
1.8 RATIONALE OF THE STUDY 
However, these complications do not occur in all individuals despite similar 
exposure to drugs, comparable demography, and other characteristics. The reasons for 
this discrepancy may be related to host genetic factors as well as other environmental 
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triggers such as nutrition. There are very few studies among HIV infected individuals 
demonstrating the link between genes regulating lipid metabolism and 
hyperlipidaemia. As increasing numbers of HIV-infected children are initiating ART, 
it becomes important to study the role of nutrition and genetic factors in the 
development of lipodystrophy and other metabolic complications among HIV-
infected children initiating ART in India. The hypothesis of this study is that HIV-
infected children on first-line ART are prone to develop lipodystrophy and 
dyslipidaemia, especially when they have a specific combination of antiretroviral 
therapy, gene polymorphism and malnutrition.  
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OBJECTIVES AND HYPOTHESIS 
 
2.1 PRIMARY OBJECTIVE  
To determine the incidence of dyslipidemia, insulin resistance (by HOMA-
IR), and body shape changes (fat redistribution like fat atrophy and central fat 
deposition as defined by anthropometry) in HIV-infected children between the ages of 
2-12 years, 24 months after initiating first-line NRTI-based anti-retroviral treatment 
regimen.  
 
2.1.1 Hypothesis 
 With the long-term use of an ART regimen consisting of 2NRTIs + 1 NNRTI 
as per the Indian ART Programme, children are prone to develop metabolic 
complications after two years of continuous ART usage by virtue of its very 
mechanism of action.  
 
2.2 SECONDARY OBJECTIVE 
To identify risk factors (nutritional and genetic) associated with the 
development of lipodystrophy syndrome in children between the ages of 2-12 years, 
24 months after initiating first-line NRTI-based anti-retroviral regimen. 
 
2.2.1 Hypotheses   
1. HIV-infected children between the ages of 2-12 years in South India who have 
a height for-age Z-score [HAZ]  of within 1 standard deviation of normal at 
the initiation of ART will maintain normal height-for-their age Z-score at 24 
months of ART but mid-arm circumference (MAC) as a surrogate of fat 
atrophy will not increase proportionately. 
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2. HIV-infected children between the ages of 2-12 years in South India who are 
stunted (as defined by a height-for-age Z-score [HAZ] more abnormal than 1 
standard deviation of normal) at the initiation of ART will not improve their 
height-for-age Z-score at 24 months of ART and mid-arm circumference will 
not increase proportionately. 
3. HIV-infected children between the ages of 2-12 years in South India who have 
a weight-for-height Z-score [WHZ] within 1 standard deviation of normal at 
the initiation of ART will maintain a normal weight for height Z-score after 24 
months of ART and waist measures will increase more than would be 
expected proportionately. 
4. HIV-infected children between the ages of 2-12 years in South India who are 
wasted (defined as a weight for height Z-score [WHZ] more abnormal than -1 
standard deviation of normal) at the initiation of ART will improve their 
weight for height Z-score at 24 months of ART. 
5. HIV-infected children with more than 2 disadvantageous single nucleotide 
polymorphism [SNPs]  in their APOA5, APOC3, APOE, CETP genes will 
have more severe dyslipidemia (TC, TGL, LDL-c, or HDL-c) and more 
abnormal HOMA-IR  than children without the polymorphism, 24 months 
after initiation of ART. 
 A better understanding of these abnormalities in children will aid in designing 
new strategies to prevent the long-term deleterious consequences of ART. 
Furthermore, genetic profiling may contribute to the identification of patients at risk 
for antiretroviral therapy-related dyslipidemia.  
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REVIEW OF LITERATURE 
 
3.1 CURRENT GLOBAL SITUATION OF THE HIV / AIDS EPIDEMIC   
From the dawn of the HIV / AIDS epidemic over seventy million people 
globally have been infected, roughly half of whom died from it leaving an estimated 
36.7 million [30.8–42.9 million] individuals living with HIV at the end of 2016. This 
figure includes 0.8% [0.7-0.9%] of adults aged 15–49 years worldwide, although the 
burden of the epidemic continues to vary considerably between countries and regions 
[38].  
An estimated 3.2 million children were living with HIV at the end of 2013, 
mostly in sub-Saharan Africa. The majority of these acquire HIV from their similarly 
infected mothers during pregnancy, childbirth, or breastfeeding. These children 
already infected need to be enrolled in continuous effective treatment to stay healthy. 
However, a significant opportunity exists to drive their numbers lower as with 
efficacious interventions the risk of mother-to-child HIV transmission can be reduced 
to 2%. Such interventions remain largely inaccessible in the most resource-limited 
countries where the burden of HIV is highest [39]. 
 
3.1.1 HIV in INDIA   
Adult (15-49 years) HIV prevalence in India was estimated at 0.26% (0.22%-
0.32%) - 0.30% among males and 0.22% among females per the report of India HIV 
Estimation 2015. The national prevalence has declined steadily from an estimated 
peak of 0.38% in 2001-03 through 0.34% in 2007 and 0.28% in 2012 to 0.26% in 
2015 [40]. This decline was noted among both adult males and females. Figure 3 
shows the estimated adult HIV prevalence in India. 
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Figure 3: Estimated Adult HIV prevalence in India between 1990-2015 (with 
uncertainty 
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In 2015, the total number of People Living with HIV (PLHIV) in India was 
estimated at 21.17 lakhs (17.11 – 26.49 lakhs) [2.12 million (1.71 – 2.65 million)] 
with females contributing about 41% of the total and children under 15 years old 
commonly thought to be 6.54%. However, estimates of total numbers of Indian 
children living with HIV vary widely from 55,000 to 220,000 [41]. Given India’s 
overall population of more than 1.34 billion people, these would appear to show a low 
prevalence of HIV infection, yet India ranks among the countries with largest 
populations living with HIV. The Southern Indian State of Tamilnadu is estimated to 
have approximately 1.43 lakhs (0.14 million) PLHIV, which indicates prevalence 
greater than the national prevalence of 0.26 [40]. 
 
3.2 ANTIRETROVIRAL TREATMENT (ART) FOR HIV INFECTED 
CHILDREN 
HIV infections are especially fatal in extremely young children as they 
progress through the disease at a much faster rate. Within the first 12 months, 33% of 
children with HIV die, 50% by 24 months and 60% by 36 months. Early detection, 
nutritional supplements, and medical treatment are essential for survival. Initiation of 
ART at the earliest possible moment is especially crucial in reducing the mortality 
and morbidity in infants and children with HIV.  
Globally, the number of children under 15 years receiving antiretroviral 
therapy (ART)  in low- and middle-income countries more than doubled between 
2009 and 2013, from 355,000 to 740,000 [42]. Yet the end of 2013, less than one 
quarter (23%, range 21–25%) of children living with HIV were receiving ART in 
low-and middle-income countries compared to more than one third (37%, range 35–
39%) of adults living with HIV. Table 1 shows the estimated number of children 
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living with HIV less than 15 years receiving ART, children needing ART and 
percentage coverage in low- and middle-income countries according to region, as of 
December 2011. 
 
Table 1: Estimated number of children living with HIV on ART 
Geographical 
region 
Reported number 
of children (0-14 
years) receiving 
ART 
Estimated number of 
children needing ART  
[range] 
Antiretroviral 
therapy coverage 
among children 
[range] 
Sub-Saharan Africa 495 700 
1 830 000 
[1600000-2 000000] 
27% [24-30%] 
Eastern and 
southern Africa 
426 800 
1 310 000  
[1200000-1400 000] 
33% [30-37%] 
West and central 
Africa 
68 900 
520 000  
[450 000-600 000] 
13% [12-15%] 
Latin America and 
the Caribbean 
17 000 
39 000  
[31 000-48 000] 
43% [35-54%] 
Latin America 13 500 
29 000  
[22 000-38 000] 
46% [36-60%] 
The Caribbean 3 500 
10 200  
[8500-12000] 
34% [29-41%] 
East, South and 
South-East Asia 
44 400 
111 000  
[51000-200000] 
40% [22-88%] 
Europe and Central 
Asia 
8 200 
7 800  
[7 500-8 200] 
>95% [>95%] 
North Africa and 
the Middle East 
900 
6 500  
[5 200-7900] 
14% [11-17%] 
Total 566 000 
1 990 000  
[1800000-2300000] 
28% [25-31%] 
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3.2.1 When to start ART  
ART is a life-long therapy, and the decision-making process for initiating 
ART relies on a clinical and immunological assessment of the individual. The 
decision should also involve an evaluation of the child’s social environment including 
the identification of a clearly defined caregiver who understands both the prognosis of 
HIV infection and the implications of ART. Tables 2a and 2b show the WHO 
classification of HIV disease based on clinical and immunological stages respectively. 
 
Table 2a: WHO classification of HIV-associated clinical disease 
HIV associated Symptoms WHO Clinical Stage 
Asymptomatic 1 
Mild Symptoms 2 
Advanced Symptoms 3 
Severe Symptoms 4 
 
 
Table 2b: WHO immunological classification for established HIV infection [43] 
HIV-associated 
immunodeficiency 
Age-related CD4 values 
<11 
months 
(%CD4+) 
12–35 
months 
(%CD4+) 
36 –59 
months 
(%CD4+) 
>5 years (absolute 
number/ mm
3 
or 
%CD4+) 
None or 
not significant 
> 30 > 30 > 25 > 500 
Mild 30-29 35-30 20-25 350 - 499 
Advanced 25 -29 20 -24 15 -19 200 - 349 
Severe < 25 < 20 < 15 < 200 or <15% 
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3.2.2 What ART to start  
Currently the standard treatment for HIV infection is three antiretroviral 
medications which in combination achieve the best possible suppression of viral 
replication to arrest the progression of HIV disease. The WHO recommends better 
implementation of pediatric ART through the development of child friendly 
formulations (like crushable, dispersible, granular, or scored tablets) but unfortunately 
many drugs do not have solid formulations in doses appropriate for pediatric use and 
some with appropriate formulations do not have all the drug components evenly 
distributed within the tablets. Table 3 shows the various first-line ART available - 
 
Table 3: First-line antiretroviral drugs of two main classes of ARVs: 
1. Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) 
Zidovudine AZT/ZDV 
Lamivudine 3TC 
Stavudine d4T 
Didanosine ddI 
Abacavir ABC 
Emtricitabine FTC 
 
 
2. Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs) 
Nevirapine NVP 
Efavirenz EFZ 
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3.2.3 Antiretroviral treatment regimens: 
The preferred option for a first-line regimen for infants and children is two 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) plus one Non-nucleoside 
Reverse Transcriptase Inhibitor (NNRTI). These 2 NRTI+1 NNRTI based regimens 
are efficacious, generally less expensive, and available without having to maintain 
cold chain. The major disadvantage of these regimens are that a single HIV mutation 
may be associated with resistance to some drugs and at the same time a single 
mutation can induce resistance to all currently available drugs in that class (NNRTI). 
Active components of these regimens may include a thymidine analogue 
NRTI [Stavudine (d4T), Zidovudine (AZT)] or a guanosine analogue NRTI [Abacavir 
(ABC)] combined with a cytidine analogue NRTI [Lamivudine (3TC)] and an NNRTI 
[Efavirenz (EFZ) or Nevirapine (NVP)]. Table 3 shows the various combinations of 
ART for pediatric initiation.  
Table 4: Summary of preferred first-line ART for infants and children 
Regimen of 2 NRTIs Plus 1 NNRTI 
d4T + 3TC + NVP AZT + 3TC + NVP ABC + 3TC + NVP 
d4T + 3TC + EFZ AZT + 3TC + EFZ ABC + 3TC + EFZ 
 
 
3.3 NATIONAL PEDIATRIC HIV/AIDS INITIATIVE 
The National Pediatric HIV/AIDS Initiative for India was launched on 30
th
 
November 2006. As on September 2016, nearly 80,634 Children Living with 
HIV/AIDS (CLHIV) were on active HIV care at ART centers and about 55,606 were 
receiving free ART [42]. Pediatric formulations of ART have greatly improved the 
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care of HIV infected children and are available at all ART centers. Although first-line 
ART is efficacious, some children do show evidence of ART failure. The national 
programme has a provision for second-line ART at Pediatric Centre of Excellence and 
ART Plus Centres, free of cost.  
3.3.1 When to start ART for children 
The decision to start ART depends on the age of the child, and clinical and 
immunological staging: 
- All children < 24 months of age with confirmed HIV infections should be 
started on ART, irrespective of the clinical or immunological stage. 
- For children aged 24 - 59 months, ART should be initiated for all children 
with Clinical Stage 3 and Stage 4 disease and/or CD4 < 25% or CD4 count     
< 750/mm
3
 
- For children aged > 60 months, ART should be initiated for all children with 
Clinical Stage 3 and Stage 4 disease and/or CD4 count < 350/ mm
3
 
In comparison to absolute CD4 counts, the CD4% in young children varies 
less within age groups. Therefore in children <60 months or 5 years of age, CD4% is 
considered in the criteria for initiating ART.  
 
3.3.2 Which ART Regimen to Start in Children [44,45] 
The recommended first line regimen for HIV-infected children > 24 months of 
age is two NRTIs plus one NNRTI.  
The preferred NNRTI is Nevirapine (NVP), but this should only be used with 
close monitoring of liver function tests in adolescent girls with CD4 count > 250 due 
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to the risk of hepatotoxicity. Efavirenz (EFV) should not be used in the following 
cases -  
- Adolescent girls who are sexually active or pregnant due to the teratogenic 
potential of EFV in the first trimester of pregnancy. 
- Children < 3 years of age or < 10 kgs due to lack of appropriate dosing 
information in for this age group. 
Previously, Stavudine was the preferred NRTI in children. Due to emerging 
toxicity, Zidovudine is now the preferred NRTI in children and Stavudine only is to 
be used in children with hemoglobin < 9 gm%.  
 
3.4 ADVERSE EFFECTS OF ANTIRETROVIRAL (ARV) DRUGS 
Clinical features suggestive of ARV-related adverse events or side effects 
must be distinguished from HIV associated conditions, opportunistic Infections, or 
other common childhood diseases. Data on drug averse events is limited in children; 
must of it is extrapolated from adult studies. Such events may be described as follows: 
- Acute, immediately after drug use 
- Sub-acute, 1-2 days after drug use 
- Late, after prolonged drug use 
Types of side effects may be classified under the following broad categories: 
a) Hematological 
Bone marrow suppression 
Anemia / Neutropenia / Thrombocytopenia, rarely 
b) Mitochondrial - especially NRTIs 
Lactic acidosis 
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Hepatic toxicity 
Pancreatitis 
Peripheral neuropathy 
c) Metabolic - Especially PIs and some NRTIs (d4T) 
Fat (Lipodystrophy, hyperlipidemia) 
Glucose (Hyperglycemia, insulin resistance, diabetes) 
Bone (osteopenia, osteoporosis, and osteonecrosis) 
d) Allergic 
Skin rash 
Hypersensitivity 
 
3.5 METABOLIC ABNORMALITIES WITH ART 
Lipodystrophy and metabolic abnormalities occur mainly with Stavudine 
(d4T) and the Protease Inhibitor and to a lesser degree with certain other NRTI drugs. 
The spectrum of abnormalities includes fat maldistribution and body habitus changes; 
dyslipidemia including hyperlipidemia; hyperglycemia; glucose intolerance including 
insulin resistance, diabetes mellitus; and bone mineral derangement like osteopenia, 
osteoporosis and osteonecrosis [4, 8, 9]. The following metabolic abnormalities with 
ART are of maximum interest- 
(i) Dyslipidemia including hypertriglyceridemia, hypercholesterolemia, low HDL 
levels, hyperglycemia.  
(ii) Lipodystrophy: Accumulation of fat and/or fat loss in distinct regions of the 
body; increased fat around the abdomen, buffalo hump, breast hypertrophy 
or  fat loss from limbs, buttocks and face  
(iii) Insulin resistance, including diabetes mellitus.  
35 
 
(i) Dyslipidemia: Dyslipidemia is a common late adverse effect of ART in 
HIV infected children in the developed world that significantly increases the long-
term risk of atherosclerotic vascular disease and may have major public health 
implications for these patients. The public health importance of atherosclerotic 
vascular disease in this extremely vulnerable population will only increase as ART 
coverage expands because HIV-infected children are expected to receive ART for life. 
Uses of NRTIs and NNRTIs, to some extent, have been implicated in the occurrence 
of dyslipidemia. In adults the NRTI drug stavudine has been linked with dyslipidemia.  
Dyslipidemia in HIV-infected children is of particular concern for several 
reasons including a linkage to preclinical atherosclerosis and hence cardiovascular 
morbidity during childhood and adolescence. Table 5 shows the grading of 
dyslipidemia based upon laboratory results. Many cross sectional studies report 
dyslipidemia in HIV infected children across the world [20, 21, 24]. Studies of ART-
related dyslipidemia in children have focused mostly on children living in developed 
countries, who make up less than 8% of the global burden of pediatric HIV infections 
(Table 6). More recent studies from the African continent also show dyslipidemia in 
HIV infected children on first-line ART [25].  
 
Table 5: Severity grading of dyslipidemia in children on ART 
Parameter (fasting) 
Mild 
(mg/dl) 
Moderate 
(mg/dl) 
Severe 
(mg/dl) 
Life threatening 
(mg/dl) 
Cholesterol 170 – 200 200 –300 >300 Not applicable 
Triglycerides Not applicable 500 - <751 751- 1200 > 1200 
Serum glucose 110 - <126 126-<251 251 – 500 > 500 
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Indian scenario  
Although there is a high prevalence of dyslipidemia reported among HIV 
infected children on ART from other parts of the world, there are not many studies 
that have reported dyslipidemia or lipodystrophy in HIV infected children from India. 
A small cross sectional observational study by Parakh et al. reported higher 
cholesterol levels in children on first-line ART compared to children not on ART 
[46]. Another cross sectional study by Mandal et al.  in 81 HIV infected children on 
NNRTI based ART has reported a high prevalence of dyslipidemia (38.3%) and 
lipodystrophy (80%). The authors found that children receiving HAART had 
hypertriglyceridemia as the most frequent lipid profile abnormality (22.2%) followed 
by hypercholesterolemia (14.8%)  [47]. 
 
Table 6: Prevalence of Dyslipidaemia in HIV-infected children on ART 
 
Author/ 
year 
Regimen 
Median 
time 
(years) 
Total no. 
of 
children 
Hyper 
TC 
(%) 
Hyper 
TGL 
(%) 
High 
LDL-c 
(%) 
Low 
HDL
(%) 
 
Ramteke S 
M et al. 
2017 
2NRTI+1PI 
or  
1 NNRTI 
- 553 22 22 14 14 
Sonego M, 
et al. 2016  
2NRTI+1N
NRTI 
5 173 15 48 10 22 
Innes S     
et al. 2016 
2NRTI+1PI 
or  
1 NNRTI 
3 100 13 9 12 13 
Arpadi      
et al. 2013 
2NRTI+1N
NRTI 
4 71 9 3 7 3 
Dapena M 
et al. 2012 
2NRTI+1PI 
or  
1 NNRTI 
10 157 24 25 - - 
Ninal 
Desai, et al 
2008  
HAART 1.6 48 
93 
 
- - - 
Torrres S, 
et al, 2005  
NRTI + PI 4 56 57 
71 
 
- - 
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European 
Pediatric 
Lipodystro
phy gp,   
2004  
d4T + 3Tc 3 477 27 21 - - 
Amaya RA,  
et al. 2002  
NRTI +  
PI / NNRTI 
 
1 
 
40 
 
73 
 
- - - 
 
 
ii) Insulin resistance:  
Disorders of the glucose metabolism, ranging from a reduction in insulin 
sensitivity to impaired glucose tolerance and diabetes mellitus, have been recognized 
in HIV-infected adults [48, 49]. The use of protease inhibitors has been associated 
with the emergence of insulin resistance, though HIV-1 infection may also 
independently be linked to decreased insulin sensitivity [50].  The same processes 
may occur in children but are less apparent clinically and hence have not been 
sufficiently studied.   
 A cohort study found the prevalence of insulin resistance in prepubertal and 
pubertal children with HIV infections to be 15.2% [51]. Table 7 details various 
reports on the prevalence of insulin resistance among children on ART. 
 
Table 7: Prevalence of insulin resistance in HIV infected children on ART 
 
Author/year 
 
Regimen 
Median 
time 
(years) 
Total no. 
of 
children 
Insulin 
Resistance 
(%) 
Geffner et al. 2011 PI based regimen - 402 15 
Lee et al. 2008 2NRTI+1NNRTI 2 96 7 
Ross R et al. 2007 2NRTI+1NNRTI - 48 52 
 
The standard technique for assessment of insulin sensitivity is the 
hyperinsulinemic-euglycemic clamp, often combined with the hyperglycemic clamp 
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to determine the adequacy of compensatory β-cell hypersensitivity [52]. Several 
fasting or ‘homeostatic’ models have been proposed as non-invasive measurement 
techniques for insulin sensitivity, with a relatively good correlation to clamp 
techniques. The Homeostatic Model Assessment-IR (HOMA-IR), fasting 
glucose/insulin ratio (FGIR), and quantitative insulin sensitivity check index 
(QUICKI) methods have been most frequently used in clinical investigations [53].  As 
a measure of IR among children, HOMA-IR has been used more often than QUICKI 
and FGIR, although the criteria for pediatric cutoff are unclear [54]. 
 
3.6 HIV ASSOCIATED LIPODYSTROPHY SYNDROME 
The metabolic changes and body fat redistribution resulting from the use of 
antiretroviral therapy described above have been regrouped into an entity called “HIV 
Associated Lipodystrophy Syndrome” [9]. The three main components are abnormal 
blood lipid profiles (mostly hypercholesterolemia and hypertriglyceridemia), insulin 
resistance, and body fat redistribution. Each of these metabolic abnormalities could 
affect the long-term outcome of HIV infected adults and children. Furthermore, fat 
redistribution and body shape changes play a role in adherence to treatment and could 
therefore affect response to ART as well. 
 
3.6.1 Pathophysiology of HIV Associated Lipodystrophy syndrome  
The patho-physiological mechanisms underlying HIV associated 
lipodystrophy syndrome has not yet been completely elucidated. Studies have 
demonstrated the contribution of protease inhibitors through the dysregulation of 
adipogenesis and contribution of nucleoside reverse transcriptase inhibitors probably 
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through mitochondrial toxicity in the development of lipodystrophy syndrome [34, 35, 
55]. NRTIs, especially stavudine have been specifically implicated in the lipoatrophy 
syndrome [56]. Mitochondrial DNA is affected not only by HIV infection but also by 
the drugs used for treatment of the infection. Exposure to the NRTI class of drugs, 
including stavudine, zidovudine and to protease inhibitors have been implicated in the 
development of lipodystrophy [25, 55]. As NRTIs are DNA anti-metabolites they 
inhibit the activity of mitochondrial DNA polymerase gamma, which is responsible 
for the replication of mitochondrial DNA. This action kicks off a series of effects 
including the depletion of mitochondrial DNA, respiratory chain dysfunction, and 
reduced energy production [57, 58]. Mitochondrial dysfunction leads to decreased 
ATP, decreased lipogenesis, and increased pro-apoptotic mediators, which result in 
fat cell death [58]. Dysregulation of cytokines like the Tumor Necrosis Factor (TNF-
α) and interleukins 1β and 6, or the expression of HIV-1 encoded proteins such as Vpr 
and Tat may also facilitate the expression of lipodystrophy syndrome [59].   
A few studies suggest that variant alleles of APOE and APOC-III contribute to 
an unfavorable lipid profile in patients with HIV. They also suggest that a complex 
interaction between genotype and ART can lead to severe hyperlipidemia [60, 61]. In 
the Swiss HIV Cohort Study (SHCS) it was found that polymorphisms in APOA5, 
APOC3, APOE, and CETP appeared to contribute to hypertriglyceridemia, while 
SNPs in genes APOA5 and CETP contributed to low HDL-C [62].  The PLIN gene is 
another major protein coating intracellular lipid droplets and modulates adipocyte 
lipolysis. Given the important role this protein plays in fat storage and metabolism, it 
is plausible that polymorphisms at this locus may be associated with lipodystrophy, 
lipoatrophy, or dyslipidemia in HIV infection [63]. Data is also available on the 
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frequency of various gene alleles involved in the disorder of lipid metabolism within 
the general Indian population. This data includes a study from an urban adult cohort 
in Chennai that revealed an association between polymorphism in the promoter region 
of apolipoprotein C-III (APOC3) and the development of metabolic syndrome and 
dyslipidemia [64]. 
The exact pathogenesis of insulin resistance (IR) in HIV-infected subjects is 
not known, but is likely to be multifactorial. IR has been attributed to HIV itself 
and/or (more likely) to the use of HAART, especially protease inhibitors (PIs) and 
nucleoside reverse transcriptase inhibitors (NRTIs) [65]. NRTIs have also been 
associated with unfavorable changes in body composition (lipodystrophy), which may 
occur de novo in untreated HIV-infected patients, but is more often seen with PIs. The 
accompanying increase in visceral fat is likely to contribute to IR, perhaps mediated 
by heightened production of resistin and/or reduced production of adiponectin by 
adipose tissue [66, 67]. 
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MATERIALS AND METHODS 
 
4.1 STUDY SETTING 
The “HIV-Associated Lipodystrophy Syndrome” (HALS) study is a 
prospective study within India to determine the incidence of dyslipidemia and 
lipodystrophy among HIV-infected children initiating ART and the influence of diet, 
drug and genes on development of abnormal lipid metabolism in these children. This 
main study enrolled and monitored HIV-infected ART-naïve children, aged 2-12 
years, at the Government ART centers  at the National Institute for Research in 
Tuberculosis and the Institute of Child Health and Children’s Hospital, Chennai, and 
St. John’s Hospital, Bangalore, India,  during the period 2011 and 2016. For this 
project children enrolled at Chennai sites-the National Institute for Research in 
Tuberculosis and the Institute of Child Health and Children’s Hospital - and who 
completed follow-up between July 2014 and December 2016 were included.  
The National Institute for Research in Tuberculosis (NIRT), formerly known as the 
Tuberculosis Research Centre, is a premier research institute in India under the Indian 
Council of Medical Research and is one of the three WHO collaborating centers for 
TB research and training in Southeast Asia. The HIV division of the Department of 
Clinical Research at NIRT is engaged in a broad spectrum of research activities 
involving children and adults infected with HIV. Such research includes clinical trials, 
observational studies, pharmacokinetic studies and nutritional intervention studies. 
Patients are recruited from peripheral clinical research units located in the state 
government hospitals in Chennai and Madurai. Longstanding collaborations exist 
between these hospitals and NIRT as well as the Government ART centers. At the 
Government ART centers linked with NIRT, approximately 15-20 HIV-infected 
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children are seen every month, of whom 6-7 are started on ART. The children are 
subsequently referred to NIRT for TB screening and enrolment in ongoing studies. 
Previously conducted pediatric HIV studies include a study to look at the markers of 
HIV disease progression on T cells as well as dendritic cell function in a cohort of 60 
HIV-infected children as well as another cohort study of HIV-infected children at the 
outpatient clinics to rule out TB; these give an idea of prior experience of NIRT in 
recruiting and conducting pediatric HIV studies.  The follow-up rates in these studies 
are over 90%. 
The Institute of Child Health and Children’s hospital (ICH & CH) in Egmore, 
Chennai is a tertiary care center for infants and children attached to the Madras 
Medical College and hospital, Chennai. The ART center at ICH and CH is a Center of 
Excellence for the management of pediatric HIV/AIDS and caters to the vast majority 
of HIV & HIV-TB coinfected children from across the Indian State of Tamil Nadu.   
 
4.2 STUDY DESIGN 
This was a prospective cohort study of HIV infected children in Chennai who 
were about to initiate ART based on then NACO recommendations (clinical and 
immunological criteria), that is, children whose CD4 percentage was below 15%, or 
CD4 cell count below their age-related cut-off, or children with WHO HIV infection 
stage III or IV. Approximately equal number of males and females in the age group of 
2 to 12 years along with appropriate controls were recruited. Considering that at 
puberty, due to hormonal changes, children may develop body shape changes akin to 
lipodystrophy the upper age limit for study enrollment was kept at 12 years, to avoid 
the influence of pubertal / hormonal changes in study participants.  
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(Puberty in HIV infected children in this part of the country is delayed compared to 
non-HIV infected children).  
The study was approved by the Institutional Review board of the National 
Institute for Research in Tuberculosis, Chennai and Madras Medical College, Chennai 
for Institute of Child Health and Children’s Hospital. A written informed consent was 
obtained from the parent/ guardian/ caretaker of the child along with assent from the 
child, wherever applicable. 
Children were enrolled in the study at baseline when they were ART naïve. 
They were followed for 24 months after the initiation of ART. The children received 
first-line ART regimen as per the then NACO recommendation consisting of 2 NRTIs 
and one NNRTI drugs. ART regimen consisting of Stavudine (d4T) / Zidovudine 
(AZT), lamivudine (3TC) and Nevirapine (NVP) were provided by the Government 
of India through the ART clinics at ICH & CH, Egmore. Children were put on 
different NRTI drugs in their ART regimen depending on their hemoglobin levels. 
Majority of the children (> 90%) received the same ART so that differences in ART 
will not confound the results of this study. 
 
4.3 STUDY POPULATION  
Inclusion criteria:  
1. HIV infected children between 2 to 12 years of age 
2. Subjects/guardians willing to sign an informed consent and allow their child 
to participate in this study. 
3. Children about to initiate ART according to Government of India criteria 
for pediatric HIV which are based on the WHO guidelines and adopted by 
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NACO. ART was started for all children in WHO Stage III or IV as well as 
those with CD4 % < 15% or CD4 counts less than 250 cells/mm
3 
(as per the 
age-related cut-off).  
 
Exclusion criteria:  
1. Serious/life threatening complications of HIV (severe diarrhea, cerebral 
toxoplasmosis)  
2. Known diabetes with or without treatment 
3. Children on corticosteroids within the last 6 weeks 
4. Children on treatment with lipid lowering agents 
5. Clinical signs of severe kwashiorkor: Generalized edema, puffy face, thin 
dry brittle hair, with skin changes like hyper pigmented patches and erythema 
dry and inelastic skin.   
HIV infected not on antiretroviral therapy (Control): This group was included 
as a control group to demonstrate that antiretroviral therapy has a role to play in the 
development of HIV associated lipodystrophy syndrome. The inclusion criteria for the 
HIV-infected children not on antiretrovirals were the same except that their CD4 cell 
counts / percentage were well above the recommended levels to initiate ART in the 
National guidelines.  
 
4.4 STUDY ENDPOINTS 
  Study endpoints included - 
 Changes in the following parameters: 
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1. weight for age and weight for height Z-scores in children between 2-12 
years 
2. body mass index (BMI) 
3. midarm circumference (MAC) 
4. fasting serum total cholesterol 
5. fasting serum LDL-c 
6. fasting serum HDL-c 
7. fasting serum triglyceride 
8. fasting serum glucose 
9. fasting serum insulin 
 
 Prevalence of single nucleotide polymorphism in APOA5 (64G>C and -
1131T>C), APOC3 (-482 C>T, -455 T>C and 3238 C>G), APOE (E2, E4 
alleles) genes, in children with metabolic and body shape abnormalities. 
 
4.5 STUDY DEFINITIONS 
1. Objective measures of body shape (by anthropometry): There are no 
precise clinical definitions for body shape abnormalities in children or adults with 
HIV.  Hence, the study utilized the norms in children in India to determine whether 
the percentiles of mid-arm circumference (MAC) and waist circumference and 
consequent changes in these circumferences measured in study participants are 
proportionate to the percentile for their overall weight and age or Z-scores.  
Fat atrophy was defined as the MAC age percentile less than the weight for age Z-
score percentile or BMI for age Z-score; central fat deposition was defined as waist 
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circumference percentile greater than the percentile for weight for age Z-score or 
BMI. Signs of fat atrophy were looked in terms of -   
 a. Face - sunken cheeks, sunken eyes, prominent zygomatic arch 
 b. Arms & Legs - skinny, prominent veins; wasting with loss of muscularity 
Signs of Central lipohypertrophy are -  
 a. Trunk - increased abdominal girth 
 b. Dorso-cervical - fat accumulation “buffalo hump” 
 
2. Hyperlipidemia: Hyperlipidemia was defined as the presence of either 
hypercholesterolemia or high LDL-c or hypertriglyceridemia (Euro Peda Lipo Group) 
 (i) Hypercholesterolemia – children with total plasma cholesterol > 200mg/dl  
 (ii) High Low-density lipoprotein cholesterol (LDL-c) of 130 mg/dl or greater 
(iii) High-density lipoprotein cholesterol (HDL-c) should not be less than 45 
mg/dl  
 (iv) Hypertriglyceridemia – plasma triglycerides > 150mg/dl  
  
 3. Peripheral Insulin resistance: Insulin resistance was defined as 
increased fasting insulin levels with normal fasting blood glucose level. Homeostasis 
Model Assessment of insulin resistance (HOMA-IR) is one of several surrogate 
measures of insulin resistance, the gold standard generally being a euglycemic insulin 
clamp study or 2 hr 75 gram OGTT.  The study measured glucose in mg/dl, and used 
the following formula:  
 HOMA-IR = [fasting glucose (mg/dL) X insulin (uU/mL)]/405 to calculate 
HOMA. The higher the HOMA-IR result, the individual exhibits more insulin 
resistance. For this study, a value of greater than 3.5 was defined as insulin resistance.   
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4. Anthropometric Indices:  Growth abnormality were classified as Stunting 
(based on height for age Z-score - HAZ), Underweight (based on weight for age Z-
score-WAZ) and Wasting (based on weight for height Z-score – WHZ). 
 (i) Height for age (HAZ) : < -3SD: severely stunted 
     -2SD to –2.99SD: moderately stunted 
 > -2SD: not stunted 
(ii) Weight for age (WAZ) :  < -3SD: severely underweight 
     -2SD to –2.99SD: moderately underweight 
 > -2SD: not underweight 
(iii) Weight for height (WHZ) : < -3SD: severely wasted 
     -2SD to –2.99SD: moderately wasted 
 >-2SD & < +2SD: normal 
 >+2SD & < +3SD: Overweight 
 > +3SD: Obese 
 
4.6 SAMPLE SIZE CALCULATION 
 To our knowledge, there is no published data on 24-month changes in 
metabolic parameters or body shape changes among HIV-infected Indian children 
started on first-line NRTI + NNRTI-based antiretroviral regimens. Therefore, this 
study calculated sample size from a similar study done in a smaller group of children 
over a shorter duration of time.  
 A cross-sectional observational study of Indian children on HAART for a 
median duration of 1.75 years showed that 9% (2/22) of children developed metabolic 
abnormalities and lipodystrophy [46].  Our previous studies have shown that almost 
45% - 55% of HIV infected children in India are malnourished [68, 69]. So, we 
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expected that 10% of the children on ART will develop one or more metabolic 
abnormalities over the 24 months of follow-up. We also expected that we would 
recruit 50% children with normal nutritional status and 50% with poor nutritional 
status at baseline. So, we hypothesized that 10% of children with normal baseline 
nutritional status will go on to develop hyperlipidemia, fat atrophy, fat deposition or 
both abnormalities, with higher rates of development in children with poor baseline 
nutritional status.    
 Expected hyperlipidemia or / and body shape abnormalities at the end of 24 
months of ART: 
a. For normal nutritional children=10% 
b. For poor nutritional Children    =25% 
For =0.05 and 1-=0.80, using two sided test N= 78 per arm 
We expect approximately 20% of participants would be lost to follow-up (drop-outs, 
deaths) by the end of 24 months.  Making this 20% upward adjustment for losses, 
approximately 95 children was required in each arm, making the total number of 
children to be included in the study to be 190 (approximately 200). This sample size 
would give us adequate power to detect differences in the incidence of hyperlipidemia 
or body shape abnormalities, 24 months after initiation of ART, between those with 
normal vs. poor nutritional status at baseline.   
 
4.7 ENROLMENT PROCEDURES 
Children were enrolled to the study at baseline, when they were ART naïve 
and were followed at 3 monthly intervals till 24 months after the initiation of ART. 
Children who were about to initiate ART according to the Government of India 
protocol were offered the opportunity to participate in this study.  The parent / 
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guardian or caretakers were thoroughly briefed in their native language about the 
study, its procedures, follow-up, and the risks and benefits of participating in this 
study. A detailed patient information sheet and informed consent was used. They were 
given time to comprehend the scope of participation in the study and ask questions.  
Their level of understanding was tested the next day and if they were willing for their 
child to be enrolled into the study, further study procedures were carried out after 
obtaining an informed written consent from the parent/guardian/caregiver. An assent 
for participating in the study was also obtained from the children who were seven 
years old or above. 
 
4.7.1 Clinical Evaluation 
Demographic data for the child and the family were collected during the 
baseline study visit. This data included route of acquisition of HIV, number and age 
of family members, economic and educational status of the family, educational status 
of the child (as appropriate), and food and housing security details. Data was also 
collected on the HIV disease stage and treatment status of the mother. In addition, a 
detailed clinical history including child’s current symptoms and signs including 
cough, skin rash, abdominal pain etc.; detailed medical and previous treatment 
history; birth and immunization history; and medical history were collected. A 
physical and systems examination of the child including general examination, 
respiratory system examination, abdominal systems examination, and anthropometry 
was done. A 24-hour dietary recall was obtained and all the details collected from the 
child at this visit at the ART center were recorded in the Case Record form specially 
designed for the study. The child was asked to attend the clinic the next day, fasting, 
for study blood draw.  
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4.7.2 Anthropometry 
Anthropometric measurements included height, weight, mid-arm 
circumference, head, chest, waist and hip circumferences along with skin-fold 
thickness at biceps, triceps, sub-scapular and suprailiac regions measured using 
Holtain skin fold calipers (UK) as described below [70]. 
           Weight: Weight was measured by standardized weighing scale, using 
electronic weighing scale placed on a firm, flat surface. The child was made to stand 
in the middle of the scale platform with the body weight being equally distributed on 
both feet. The child was weighed in kilograms to the nearest 0.1 kg (100 grams).  
Height: As the study included only children aged 2-12 years, height was 
measured only standing. The child was made to stand barefoot on a flat surface that is 
at a right angle to the vertical board of the stadiometer. The child was asked to inhale 
deeply and maintain a fully erect position without altering the load on the heels. For 
smaller children, marking against inch tape on the wall was used to measure the 
child’s height. 
Circumferences: The tape measure used was flexible but inelastic.  
Measurements were taken on the right side of the body. For each circumference, the 
tape was placed around the site perpendicular to the long axis of that part of the body.  
(i) Mid-Arm Circumference:  For this measurement the child was made to 
stand erect, with the arms hanging freely at the sides of the trunk and with the 
palms facing the thighs. The midpoint was located with the subject’s elbow 
flexed to 90
o 
with the palm facing superiorly toward the ceiling. The lateral tip 
of the acromion was located. A tape was placed so that it was touching the 
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skin, but not compressing the soft tissues, and the circumference was recorded 
to the nearest 0.1 cm.  
 
(ii) Waist circumference: The measurement was made over minimal clothing. 
The inelastic tape was placed around the child at the level of the natural waist, 
which is the narrowest part of the torso. 
 
(iii) Buttocks (Hip) Circumference: The child was made to stand erect with 
arms at the sides and feet together. An inelastic tape was placed around the 
buttocks without compressing the skin. The measurement was recorded to the 
nearest 0.1 cm.  
Skinfolds thickness 
(i) Triceps Skinfold: The triceps skinfold was measured in the midline of the 
posterior aspect of the arm (see Arm Circumference). The triceps skinfold was 
picked up with the left thumb and index finger, approximately 1 cm proximal 
to the marked level, and the tips of the calipers were applied to the skinfold at 
the marked level. The thickness was recorded to the nearest 0.1 cm. 
(ii) Subscapular Skinfold: The subscapular skinfold was picked up on a 
diagonal, inclined infero-laterally approximately 45
o
 to the horizontal plane in 
the natural cleavage lines of the skin. The site just inferior to the inferior angle 
of the scapula was pinched.  
(iii) Supra Iliac Skinfold: The supra iliac skinfold was measured in the mid-
axillary line immediately superior to the iliac crest.  
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The Z-scores for weight and height were computed based on the child’s age 
and gender using the EPI-NUT component of the EPI-INFO 2002 software package 
(version 3.4.3) from CDC (based on NCHS reference median values) and the 
ANTHRO and ANTHROPLUS software from WHO [71]. The WHO Global 
Database on Child Growth and Malnutrition recommends a cut-off z-score of <−2 SD 
to classify low weight-for-age (underweight), low height-for-age (stunting), and low 
weight-for-height (wasting) as moderate and a Z-score of <−3 SD to define severe 
undernutrition [72]. Waist/Hip ratio (WHR) and Waist/Height ratio (WHtR) were 
calculated. Data on body shape was obtained at tri-monthly intervals.   
 
4.7.3 Nutritional Assessment  
(i) 24-hour Dietary Recall: Both at baseline and subsequently at every 3 
monthly visits, a dietary assessment method of “24-hour dietary recall” was used to 
collect the dietary intake of the child from the child and caretaker. The 24-hour recall 
was selected because it does not require the mother or caregiver of the child to be 
literate; it is a technique without geographic or cultural bias and is valid for group 
mean nutrient estimates [73]. The 24-hour recall consists of asking the participant and 
the participant’s mother or care giver to list aloud to the study nurse/coordinator all 
food and beverages that the child consumed during the previous 24-hour period, 
including the time that each food or beverage was consumed. All foods and 
beverages, vitamin supplements, and all non-prescription medications were recorded 
on the recall form. Standard templates of shapes were used to help quantify portion 
sizes for appropriate foods for South India. These templates were then decoded using 
“Digest” software to derive the energy and nutrient intakes of the child using the 
calculated / known nutritive values of Indian foods [74]. The “Digest” software has 
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been developed in South India and includes the nutritive values for over 650 Indian 
foods. This software is used by various national organizations, planners and academic 
research institutions. Data generated based on the 24-hour recall included nutrient 
estimates for total energy, protein, carbohydrates, fats, and micronutrients.  
(ii) Food Insecurity: Household food insecurity was only assessed at the 
baseline visit using the Household Food Access Insecurity questionnaire [75].
 
Food 
insecurity was not assessed for children living in institutions or residential homes. The 
food insecurity questionnaire is a dietary assessment tools that was developed and 
validated as part of ongoing trials on nutrition and infection in India.  
 
4.7.4 Evaluations of laboratory parameters 
From children initiating ART, 10ml of blood in fasting state was collected by 
venipuncture at baseline (ART naïve) to carry out various tests including complete 
blood count, lipid profile, blood glucose, serum insulin, C-reactive protein (CRP), 
CD4 percentage, CD4 cell counts, and HIV-1 viral load. After initiation of ART 
subsequent collections were made in the at 6
th
, 12
th
, 18
th
 and 24
th
 months by 
venipuncture either after overnight fasting or a bare minimum of 4 hours fasting, for 
lipid profile, blood glucose, serum insulin, C-reactive protein (CRP), CD4 percentage, 
CD4 cell counts and HIV-1 viral load. Blood was processed and stored according to 
standard protocols.  
(i) Hematology & Immunology parameter (CD4, CD8, CD38) were detected using 
flow cytometry (Beckman Coulter Epics XL)  
(ii) HIV-1 Viral load: HIV-1 viral load in the plasma was measured by using the 
Roche COBAS AmpliPrep/ COBAS Taqman HIV-1 Test v2.0 and expressed as 
log copies/ml. 
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(iii) Fasting glucose and fasting insulin: Insulin resistance is defined as increased 
fasting insulin levels with normal fasting blood glucose levels. The measure 
used is the Homeostasis Model Assessment (HOMA) which calculates insulin 
resistance based on the fasting insulin-glucose product, divided by a constant: 
Glucose x Insulin /   405 where Glucose is given in mg/dl and Insulin is given in 
μU/ml. 
(iv) Fasting Lipids: The lipid profile including total cholesterol, HDL cholesterol, 
LDL cholesterol and triglycerides were measured on all participants using an 
automated analyzer (Olympus AU400, Japan) using standard laboratory 
technique. 
(v) Gene polymorphism studies (Real time PCR): Whole blood was collected in 
EDTA vacutainer tubes and then DNA was extracted using the Qiagen Blood 
DNA extraction kit. SNP’s in genes were detected employing the Real Time 
PCR method.  
 
4.8 STUDY SCHEDULE 
All HIV infected children attending the ART clinics at the Government 
hospitals were screened for inclusion. Children meeting the eligibility criteria were 
enrolled to the study after parents or legal guardians provided informed consent or 
after obtaining assent. Clinical management, provision of ART or any treatment for 
HIV associated complications or conditions, diagnostic investigations and 
management of adverse reactions were all as per the national (NACO) guidelines and 
were responsibility of the  site (not study) physicians.  
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During the baseline and follow-up sessions with the child, the following 
investigations were performed: 
 
Table 8: Study Schedule  
 
BL 
(naïve) 
3 
mon 
6 
mon 
9 
mon 
12 
mon 
15 
mon 
18 
mon 
21 
mon 
24 
mon 
Informed consent x - - - - - - - - 
Medical history x x x x x x x x x 
Demographics x x x x x x x x x 
Dietary intake x x x x x x x x x 
Mother’s health x x x x x x x x x 
Height x x x x x x x x x 
Weight x x x x x x x x x 
MAC x x x x x x x x x 
Chest circum. x x x x x x x x x 
Waist circum x x x x x x x x x 
Hip circumference x x x x x x x x x 
Biceps SFT x x x x x x x x x 
Triceps SFT x x x x x x x x x 
Subscapular SFT x x x x x x x x x 
Suprailiac SFT x x x x x x x x x 
TC x - x - x - x - x 
LDL x - x - x - x - x 
HDL x - x - x - x - x 
TG x - x - x - x - x 
Glucose x - x - x - x - x 
Insulin x - x - x - x - x 
CRP x - x - x - x - x 
CD4 x - x - x - x - x 
Viral load x - x - x - - - x 
snps x - - - - - - - - 
ART Adherence x x x x x x x x x 
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4.9 INITIATION OF ANTIRETROVIRAL TREATMENT 
Antiretroviral therapy is initiated in all HIV infected children after baseline 
evaluation as per the national guidelines and ART programme. The child received one 
of the following first-line regimens as per the guidelines - 
I. Zidovudine + Lamivudine + Nevirapine [ZLN]  
II. Stavudine + Lamivudine + Nevirapine [SLN]  
III. Zidovudine + Lamivudine + Efavirenz [ZLE]  
IV. Stavudine + Lamivudine  + Efavirenz  [SLE] 
 
The children were requested to visit the clinic every month for collecting their 
antiretroviral drugs. A patient-centered approach was used to promote adherence and 
the same was assessed by pill counts with reinforced counselling during their monthly 
follow-up visit. Patients who did not return to collect the drugs at their scheduled 
visits were contacted either telephonically or by home visit. Chemoprophylaxis was 
given as per the national guidelines. The children were screened for TB before 
initiating ART and if found to be positive for TB, then anti-TB treatment was initiated 
first with ART initiation 2-4 weeks later. When inpatient care was necessary, children 
were hospitalized at the Institute of Child health and Children’s hospital.   
 
4.10 STATISTICAL ANALYSIS  
The window of +/- 1 month was considered acceptable for a quarterly follow 
up visit. The distributions of all variables were checked cross-sectionally, at each 
time-point (baseline, 3, 6, 9, 12, 15, 18 and 24 months).  All unusual values were 
checked and verified. Mean median, 25
th
 and 75
th
 percentiles were determined for all 
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continuous variables. Univariate frequencies were calculated for all categorical 
variables.   
The study outcomes for HIV infected children developing body shape changes 
(fat atrophy and central fat deposition) and metabolic abnormalities while on ART 
included changes in the following parameters from baseline to 24 months - 
 1. Weight for age and weight for height Z-scores 
 2. Body mass index (BMI) 
 3. Mid-arm circumference (MAC) 
 4. Fasting serum total cholesterol, LDL-c, HDL-c 
 5. Fasting serum triglyceride 
 6. Fasting serum glucose 
 7. Fasting serum insulin   
8. Development of peripheral fat atrophy and/or central fat deposition, as 
defined by objective measures (fat atrophy: having a MAC-for-age percentile 
less than their weight-for-age or BMI percentile; fat deposition: having a waist 
circumference-for-age percentile greater than their percentile for weight-for-
age or BMI) 
9. Development of peripheral fat atrophy and/or central fat deposition, defined 
by subjective measures (nurse/study coordinator observations) 
The proportions of children with dyslipidemia within different groups were 
estimated and compared using the chi-square test.  For this analysis, the cutoff levels 
for abnormal lipids were defined as follows: hypertriglyceridemia as TGL>150mg/dl; 
hypercholesterolemia as TC> 200 mg/dl (borderline elevation if TC between 170-
199mg/dl); LDL-c >130 mg/dl and HDL-c <40mg/dl for defining abnormal values 
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[76, 77]. HOMA IR cutoff point for diagnosis of insulin resistance in children is taken 
as > 3.5 [78].  A WHR ratio of 0.9 in boys and 0.8 in girls was taken as the cut-off 
while 0.5 was taken as cut-off for WHtR [79]. The nutritive value of the diet 
consumed by the child was compared with the normal recommended dietary 
allowance for that age-group. Immunosuppression in children was defined based upon 
the WHO algorithm of staging of HIV/AIDS as severe, advanced, mild, and no 
immunosuppression based on CD4% for children aged 13-59 months and on CD4 cell 
counts for children 5 years or above [WHO 2005].  Immunologic failure was defined 
as a decrease in CD4 cell count of > 30% from baseline while immunologic recovery 
was defined as an increase in CD4 count >25% from baseline. Virologic failure was 
defined as HIV-1 RNA >1,000 copies/ml at 48 and 96 weeks after ART initiation. 
Genotypic drug resistance testing was performed for children with virologic failure.   
 The incidence rate of hyperlipidemia or peripheral fat atrophy and central fat 
deposition was determined for those children without the abnormality at baseline. The 
study assessed the relationship of gender, age, weight for age Z-score (WAZ), height 
for age Z-score (HAZ), weight for height Z-score (WHZ), HIV-1 RNA levels, food 
security with dyslipidemia and insulin resistance by using Multivariate logistic 
regression and general linear models. Factors that were found to be significant in the 
univariate regression model were only taken for Generalized Linear Model using 
MANOVA. Generalized Linear Model (GLM) deals with more than one dependent 
variable and one or more independent variables. Multivariate analysis of variance 
(MANOVA) is an extension of the univariate analysis of variance (ANOVA). In an 
ANOVA the statistical differences on one continuous dependent variable is examined 
against independent grouping variable. The MANOVA extends this analysis by taking 
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into account multiple continuous dependent variables, clubs them together into a 
weighted linear combination or composite variable. The MANOVA compares 
whether or not the newly created composite variable differs by the different groups or 
levels of the independent variable. MANOVA involves two-steps namely the 
significance test to look for are there any significant differences and post hoc test, if 
significant differences exist, where do they lie. In this way the MANOVA essentially 
tests whether or not the independent grouping variable simultaneously explains a 
statistically significant amount of variance in the dependent variable. We tested the 
presence or absence of polymorphisms in selected genes (SNPs rs662799 and 
rs3135506), dietary patterns and type of ART regimen as the dependent variables and 
the effect of various independent factors described above for the risk of developing 
hyperlipidemia or fat redistribution in the study children. Similar analysis was also 
performed to determine the predictors of virologic failure while on ART. The chance 
of developing metabolic abnormalities or body shape changes among those who have 
the risk factors was compared to those who did not have the risk factors. Variables 
that were examined as potential confounders for most outcomes included age, gender, 
CD4%, clinic site, ART regimen, and the mother’s clinical status. Data analysis was 
performed using SPSS software, version 19.0 (SPSS). 
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62 
 
RESULTS 
 
5.1 DEMOGRAPHIC PROFILE OF THE STUDY SUBJECTS  
The “HALS” study cohort consisted of ART naïve HIV-infected children 
between the age ranges of 2–12 years. After obtaining informed consent, these 
children underwent the baseline screening procedures and study investigations as 
explained in the methods section and were initiated on ART. All children were 
followed up every 3 months as per the study procedure. A cohort of two hundred HIV 
infected children initiated on ART and on follow-up in Chennai, during the period of 
July 2014 to December 2016 was included for this analysis.  
Among the children enrolled, there were almost equal numbers of males 
(51%) and females (49%) (Figures 4a & 4b). There were 98 girls with a mean ± 
standard deviation (SD) age of 7.5 ± 3.0 years and 102 boys with a mean ± SD age of 
7.9 ± 3.3 years. 
The mean ± SD weight of the girls in this cohort was 17.6 ± 6 kg and their 
mean ± SD body mass index was 14.0 ± 2.2 indicating moderate to severe 
malnutrition. Figures 4a & 4b show the gender- and age-wise distribution of the 
children. A majority of the 98 girls attended school, versus a quarter of all children 
who, were not attending school even though they were school-aged. 
Of the 102 boys, the mean ± SD weight was 18.2 ± 5.8 kg and the mean body 
mass index was 13.9 ± 1.5, far below the normal for their age. Majority of the boys 
attended school. Figure 5 illustrates the number of girls and boys in various school 
classes. Almost 50 children (26 boys and 24 girls) of school-going age were not going 
to school for varied reasons. 
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Figure 4a: Gender distribution of children in the cohort 
 
 
64 
 
Figure 4b: Age-wise distribution of boys and girls in this cohort  
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Parental history 
About three-quarters of the children were from house-holds with a single 
parent. In this cohort, 107 (50%) of the children were brought to ART center by their 
mothers, 37 (19%) by their fathers, 23 (12%) by their grandparents and the rest by 
caregivers. There were 146 mothers alive with majority of them in the age group of 
20-30 years while there were 116 fathers alive, majority in the age group of 31-40 
years. A further 17% were in foster-care while 11% were under institutional care. 
Also there were more mothers who were not educated. Table 9 shows the 
characteristics of the parents who were alive of the children in the cohort. Figure 6 & 
7 are graphical representation of the parent’s age and educational status respectively. 
 
Table 9: Characteristics of the parents of children 
Characteristics Father Mother 
Status   
Alive 116 146 
Dead 69 38 
Not known 16 18 
Age in years   
Not known 0 5 
< 20 years 0 1 
20 – 30 17 75 
31 – 40 66 62 
41 – 50 29 3 
51 - 60 4 0 
Education   
Not known 23 45 
Primary school 25 26 
Secondary school 26 29 
High school 32 37 
College 10 9 
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Figure 5: Bar chart comparing the number of girls and boys going to school 
 
 
Figure 6: Age distribution of parents of the children  
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Majority of the parents were daily wage earners – either coolie or daily 
laborers. Only around 20% of the fathers were drivers by occupation, while 40% of 
the mothers were home makers. Table 10 shows the income status of the care giver. 
About one-half of the family earned less than Rs.5000 per month, while 24% were 
earning between Rs.5000 – 10,000 per month.  
 
Table 10: Income status of the caregivers 
Income bracket per month Numbers Percentage 
< Rs.3000 / month 48 24 
Rs.3001 – 5000 / month 49 25 
Rs 5001 – 10,000 / month 47 23.5 
> Rs.10,000 / month 16 8 
Not known 40 20 
 
 
Birth history 
 Majority (96%) of the children had acquired the infection perinatally from the 
mother through vertical transmission while 8 children had acquired the infection 
through blood transfusions. The birth delivery method was unknown for 14% of the 
children as the child’s caregiver did not have that information. Of the rest, 71% of the 
children were born by normal delivery and 15% by caesarean section. 69% of the 
parents or caregivers did not know whether the mother had received antiretroviral 
therapy during pregnancy and delivery, but the majority (80%) knew that the child 
was breast-fed. Less than a quarter of the newborns had received ART at birth. Only 
105 children had their birth-weight recorded, of which 45% were underweight at birth 
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with a birth-weight of < 2.5kgs. 13% of the mothers / caregivers reported that their 
child showed delayed developmental mile stones. 
 
5.2 CLINICAL FEATURES 
Most of the children were in WHO HIV clinical infection stage III or IV when 
enrolled.  Seventy nine (39.5%) children were in WHO Stage IV, 84 (42%) in stage 
III, 21 (10.5%) in stage II and 16 (8%) were in stage I (Tale 11). Figure 8 shows the 
gender-wise staging of HIV infected children in the cohort 
 
Table 11: WHO Clinical Staging of HIV infected children  
S. No. WHO Clinical Staging Number (%) 
1 Stage I 16 (8) 
2 Stage II 21 (11) 
3 Stage III 84 (24) 
4 Stage IV 79 (40) 
 
In the cohort there were thirty-two children (16%) who had received anti-
tuberculosis treatment (ATT) in the recent past (less than 6 months ago) or were 
diagnosed with TB, pulmonary or extra pulmonary, at the time of screening for ART 
(Table 12). Figure 9 shows the number of children on anti-tuberculosis treatment in 
the cohort. 
Table 12: Children on Anti-tuberculosis treatment  
 Numbers Percentage 
Girls 13 / 98 13.2 
Boys 19 / 102 18.6  
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Figure 7: Educational status of parents of children in the study 
 
 
 
 
Figure 8: Gender-wise distribution of children in WHO clinical staging of HIV  
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The majority (66%) of the children were symptomatic at the time of attending 
the ART center and therefore found to be eligible for ART initiation. 35% had 
respiratory complaints followed by skin infection (either extensive furunculosis, 
papulo-pruritic dermatitis or herpes zoster, all characteristics of WHO clinical stage 
III HIV/AIDS). They presented a varied set of symptoms including vomiting, 
diarrhea, extensive oral ulcers, thrush, recurrent pneumonia, and meningoencephalitis. 
Table 13 shows the presenting symptoms of children (Figure 11a & 11b) 
 
Table 13: Presenting symptoms of Children in the cohort 
S. No. Symptoms Number (%) 
1 Asymptomatic 68 (34) 
2 Cough with or without sputum 44 (22) 
3 Cough with fever 25 (13) 
4 Skin manifestations (pruritis / rash/ PPD/herpes) 19 (9.5) 
5 Fever 14 (7) 
6 Diarrhea 6 (3) 
7 Others (parotitis/fits/vomiting/) 10 (5) 
 
 
Physical examination of children revealed that more than half of the children 
in the cohort were stunted (57%) and underweight (62%) for their age (Table 14). 
Figure 10 shows the gender wise growth characteristics. This was observed uniformly 
in both the genders. Their mean WAZ, HAZ and WHZ-scores were -2.2 + 1.0; -2.2 + 
1.5 and -1.3 + 1.2 respectively. Stunting was more obvious with increasing age (0-4 
years: 48%, 4-6 years: 49%; 6-9 years: 52% and >9yrs : 60%), while underweight was 
common among children <4yrs (63%) and >9yrs (62%). 78% of boys and >95% of 
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girls in the cohort had a Waist-Hip Ratio (WHR) above normal cut-off and 31% had a 
Waist-Height Ratio (WHtR) > 0.5 at baseline. 
 
Table 14: Growth characteristics of the children 
Children characteristics Values (%) 
N (%) of children who are underweight (<-2SD for WAZ) 124 (62.0) 
N (%) of children who are stunted (<-2SD for HAZ) 113 (56.5) 
N (%) of children who are wasted (<-2SD for WHZ) 43 (25.9) 
 
Further, children were categorized by their age and were examined for 
stunting and underweight. Stunting became very obvious with increasing age as 
shown in table below. 
 
Table 15: Age-wise distribution of growth characteristics 
Nutritional status < 5years (n=42) 
N(%) 
5-8 years (n=59) 
N (%) 
9-12 years (n=99) 
N (%) 
HAZ < -2SD 19 (16.8) 33 (29.2) 61 (54.0) 
HAZ > -2SD 23 (26.4) 26 (29.9) 38 (43.7) 
WAZ-score  <-2SD 29 (23.4) 34(27.4) 61(49.2) 
WAZ-score  >-2SD 13 (17.1) 25 (32.9) 38 (50.0) 
WHZ-score  <-2SD 16(37.2) 14(32.6) 13(30.2) 
WHZ-score  >-2SD 26(21.1) 45(36.6) 52(42.3) 
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Figure 9: Number of children on anti-tuberculosis treatment  
 
 
 
Figure 10: Gender wise distribution of growth characteristics  
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 Figure 11a: Presenting symptoms of children in the cohort 
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Figure 11b: Chart showing the salient findings of physical examination of 
children 
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5.3 HOUSEHOLD FOOD ACCESS INSECURITY SCORE (HFAIS) 
 The study collected household food security data only from children living 
with parents or in foster care. Twenty-one institutionalized children were not included 
for this analysis. Food security data using the HFAIS was collected from the 
caregivers of 179 children -of whom 95 (53%) were found to have some form of food 
insecurity. After comparing the baseline characteristics between the food secure and 
the food insecure groups the study did not find any difference between the two groups 
at baseline or pre-ART period (Table 16). All the children were started on ART and 
followed for 24 months of study period. 
 
Table 16: Baseline characteristics of 179 children as per their food security status 
Characteristics 
 
Food secure 
(n=84) 
Mean (SD) 
 
Food Insecure 
(n=95)  
Mean (SD) 
 
P value 
Age in years 7.7 (3) 7.5 (3) 0.36 
Male: Female n (%) 102 (51) : 98(49) 51(46) : 44(54) 0.62 
Weight in kg 17.9 (5.8) 17.3(5.9) 0.41 
Height in cm 111.9 (17.0) 110.3(17.4) 0.51 
 BMI  13.9 (1.5) 13.8(1.6) 0.28 
Median CD4 %  
(IQR) 
451.5 
[292-692] 
459 
[269-639] 
0.67 
Median Viral Load  
(IQR) 
105000 
[16022-315240] 
105965 
[18480-347525] 
0.55 
 HAZ  -2.2(1.4) -2.2(1.3) 0.74 
WAZ  -2.2(1.0) -2.3(0.9) 0.44 
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5.4 DIETARY INTAKE ASSESSMENT  
The daily food intake of the children was assessed by a 24-hour dietary recall 
questionnaire using standardized measuring cups and ladles. These were shown to the 
child and the caregiver to measure the amount consumed. The raw data thus obtained 
was fed into a dietary software package called “Digest” customized for this particular 
study. When details of food consumed are entered into “Digest” it returns the break-
up of calories, protein, fat and minerals present in the child’s diet. Table 17 shows a 
comparison of the nutritional value of the actual diet consumed by these children 
against the recommended dietary allowances (RDA) provided by the ICMR-National 
Institute of Nutrition for children for their age group. The mean energy intake was 
less than the Recommended Dietary Allowances (RDA) in children >4 years of age 
but was normal in youngest groups (Figure 12a & 12b). Iron, folate and calcium 
intake were significantly lesser than RDA across the different age groups. Fat intake 
was almost 100% of the RDA in children >4yrs of age. 
 
Table 17: Dietary intake of children compared to age specific RDA  
 
Dietary 
composition 
Age of Children (years) 
0-4 years 
Mean (SD) 
> 4-6 years 
Mean (SD) 
> 6-9 years 
Mean (SD) 
CLHIV RDA 
P 
value 
CLHIV RDA 
P 
value 
CLHIV RDA 
P 
value 
 
Body weight 
 
10.2 
 
12.9 
 
0.00 
 
13.4 
 
18.0 
 
0.00 
 
15.1 
 
25.1 
 
0.00 
 
 
Energy 
(kcal/day) 
 
938.1 
(444) 
 
1060 
 
0.29 
 
1018.7 
(378.8) 
 
1350 
 
0.00 
 
1364.6 
(573.3) 
 
 
1690 
 
0.01 
 
Protein 
(gm/day) 
 
30.3 
(13.5) 
 
16.7 
 
0.01 
 
32.3 
(13.2) 
 
20.1 
 
0.00 
 
40.9 
(21.4) 
 
 
29.5 
 
0.02 
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Visible Fat 
(gm/day) 
 
21.1 
(12.9) 
 
27 
 
0.09 
 
29.6 
(15.4) 
 
25 
 
0.14 
 
30.4 
(17.7) 
 
 
30 
 
0.89 
 
Calcium 
(mg/day) 
 
245 
(147.2) 
 
600 
 
0.01 
 
270.1 
(207.3) 
 
600 
 
0.00 
 
329.4 
(264.7) 
 
600 
 
0.00 
 
Iron  
(mg/day) 
 
5.4 
(3.8) 
 
9 
 
0.002 
 
5.5 
(2.8) 
 
13 
 
0.00 
 
9.2 
(8.7) 
 
16 
 
0.00 
 
 
Dietary 
Composition 
Mean (SD) among CLHIV between 10-12 years old 
Boys (n=41) Girls (n = 29) 
CLHIV RDA 
P 
value 
CLHIV RDA 
P 
value 
Body weight 
 
22.7 
 (4.1) 
34.3 0.00 22.8 
 (5.7) 
35 0.00 
Energy (kcal/day) 
 
1481.4 
(518.6) 
2190 0.000 1566.4 
(651.8) 
2010 0.001 
Protein (gm/day) 
 
52.1  
(22.6) 
39.9 0.001 50.4 
 (27.4) 
40.4 0.06 
Visible Fat 
(gm/day) 
 
36.1  
(19.6) 
35 0.73 33.2 
 (18.5) 
35 0.60 
Calcium (mg/day) 
 
420.3 
 (240.9) 
800 0.000 394.1 
 (312.3) 
800 0.000 
Iron (mg/day) 
 
11.3 
(10.4) 
21 0.00 14.7 
(31.6) 
27 0.04 
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Figure 12a: Mean Intake of macro- & micronutrients  
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Figure 12b: Mean Intake of macro- & micronutrients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Micro/macro nutrients vs. RDA
E
ne
rg
y
C
al
ci
um
P
ro
tie
n
Fa
t
Ir
on
Fo
lic
 A
ci
d
0
50
100
500
1000
1500
2000 Actual
RDA
p=0.00
p=0.00
p=0.89
p=0.00
p=0.00
10-12 yrs(Boys)
M
e
a
n
Micro/macro nutrients vs. RDA
En
er
gy
C
al
ci
um
Pr
ot
ie
n
Fa
t
Iro
n
Fo
lic
 A
ci
d
0
50
100
500
1000
1500
2000
2500
Actual
RDA
p=0.00
p=0.00
p=0.31 p=0.00
p=0.00
10-12 yrs(Girls)
M
e
a
n
80 
 
5.5 BASELINE LABORATORY PARAMETERS 
 At the baseline while ART naïve, the majority of the children were in the 
advanced stages of HIV disease with the mean CD4 percentage at 16.1 + 9.  Based on 
WHO guidelines (CD4% < 19% for children <5 years of age while CD4 cells < 350 
cells /mm
3 
for children > 5years of age), 63% of children <5 years of age and 50% of 
children >5 years of age had advanced or severe immunosuppression. Median viral 
load was estimated at 105,000 (range: 16022-315246) copies/ml. The majority of the 
children were anemic. Table 18 shows the severity of disease in the cohort based on 
gender.  
Table 18: Severity of HIV disease in the study cohort 
Children characteristics All Boys Girls 
Median HIV Viral load (IQR) 
105000 
(16022 - 315246) 
109166 85420 
Median CD4 cell count (IQR) 451.5 (292 – 692) 446 452.5 
Mean CD4% (SD) 16.1 ± 8 .9   
Mean Hemoglobin (gm %) 10.8 + 1.5 10.6 (2) 10.6 (1.5) 
 
Table 19a shows the fasting serum lipid, insulin, and blood glucose levels of 
children in this cohort. Except for serum HDL-cholesterol levels, the mean serum 
lipid levels (TC, TGL and LDL-c) were within the normal range.  
 
Table 19a: Fasting serum lipid, insulin and blood glucose of HIV infected 
children 
 
Biochemical parameter (mg/dl) Baseline  (mean + SD) 
Total Cholesterol  134 ± 34.2 
LDL cholesterol 75.1 ± 29.8 
HDL cholesterol 31.4 ± 10.2 
Triglycerides 136.4 ±73.0 
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Glucose 82.2 ± 10.4 
CRP (Median, IQR) 2 ( 0.6 – 7.2) 
Sr. Insulin (Median, IQR) 2.7 (1.6 – 5.8) 
HOMA-IR (Median, IQR) 0.5 (0.3 – 1.2) 
 
A considerable number of ART naïve HIV infected children showed abnormal 
lipid levels at the baseline. Around 30% of children had higher serum triglycerides 
than normal, and 75% had lower than normal (Table 19b). Borderline elevation of TC 
(170-199mg/dl) was seen in 8% of the children. Insulin resistance (HOMA-IR >3.5) 
was found in 7% of children and was higher in the older children. The proportion of 
children with any degree of dyslipidemia did not differ significantly by gender, age or 
stunting (<-2SD for HAZ). Overall, dyslipidemia, in terms of any abnormal TGL, TC, 
LDL-c but not HDL-c, was seen in 39% of children (n=78) in the study cohort. These 
features indicate HIV disease in an advanced stage and explaining the condition of 
these children when observed at the ART center during initiation.   
 
Table 19b: Proportion of children showing lipid levels above normal   
Biochemical parameter (mg/dl) Proportion of children N (%) 
Total Cholesterol > 200 5 (2.5) 
LDL cholesterol > 130 7(3.5) 
HDL cholesterol < 35 114 (57) 
HDL cholesterol < 40 158 (79) 
Triglyceride > 150 58 (29) 
Glucose > 100 8 (4.1) 
Serum insulin > 8 µ/ml 30 (15) 
HOMA-IR  ≥ 3.5 13 (6.7) 
hs-CRP 3-10mg/dl 75 (37.9) 
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5.6 ANTIRETROVIRAL REGIMEN 
All children in the study were initiated on a 2NRTI + 1 NNRTI-based regimen 
(Table 20). The choice of NRTI was either Stavudine or Zidovudine depending upon 
the child’s hemoglobin level. During the initial phase of the study, children were 
initiated on a Stavudine-containing regimen (SLN or SLE), but subsequent to a 
change in the national policy, an increasing number were initiated on a Zidovudine 
containing regimen (ZLN or ZLE). This switch was made due to Stavudine induced 
lipoatrophy reported in studies from other countries. The type of NNRTI used, 
Nevirapine or Efavirenz, was decided based upon the age of the child and the 
presence or absence of a tuberculosis co-infection.  
 
Table 20: Various combinations of ART used in the National Programme 
ARV regimens Frequency 
N (%) 
Abacavir + Lamivudine + Efavirenz (ALE) 9 (4.5) 
Abacavir + Lamivudine + Nevirapine  (ALN) 22 (11) 
Stavudine + Lamivudine + LPV/R 1 
Stavudine + Lamivudine + Efavirenz (SLE) 11 (5.5) 
Stavudine + Lamivudine + Nevirapine  (SLN) 28 (14) 
Zidovudine + Lamivudine + Efavirenz (ZLE) 23 (12) 
Zidovudine + Lamivudine + Nevirapine (ZLN) 106 (53) 
 
65% of the children in the cohort received a Zidovudine-containing regimen, 
20% were started on a Stavudine-containing regimen, and another 15% were started 
on an Abacavir containing regimen (Abacavir is another NRTI that was available in 
National Programme and was used when the child’s hemoglobin was low and hence 
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could not be initiated on Zidovudine containing regimen). Figure 12 shows the actual 
number of children in various ART regimens. 
 
5.7 GENE POLYMORPHISM 
 The study looked for the presence of specific genotypes associated with blood 
cholesterol levels in this population and found that they followed the Hardy Weinberg 
equilibrium, as can be seen from the Table 21 below.  
 
Table 21: Genetic polymorphisms associated with dyslipidemia 
Gene SNP  Genotype Frequency % 
APOA5 rs662799 CC 5 2.5 
  TC 55 28.1 
  TT 136 69.4 
 rs3135506 GC 10 5.1 
  GG 186 94.9 
APOC3 rs2854116 CC 67 33.5 
  TC 92 46.0 
  TT 33 16.5 
 rs2854117 CC 27 13.5 
  GC 92 46.0 
  GG 71 35.5 
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Figure 13: Number of children on various antiretroviral regimens 
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5.8 RELATIONSHIP BETWEEN NUTRITIONAL STATUS, DISEASE 
SEVERITY AND DYSLIPIDEMIA  
 
Overall, 39% of the children had evidence of dyslipidemia; the most common 
abnormality was low HDL-c (79%), followed by hypertriglyceridemia (29%). Insulin 
resistance (HOMA-IR >3.5) was seen in 18.5% of the children in the group. 
Dyslipidemia did not differ by gender and age but differed significantly with disease 
severity. Children with higher viral load had increased serum triglycerides, 
corroborating the fact that with HIV disease progression is associated with an elevated 
serum triglyceride levels.  
 
Table 22a:  Proportion of children with dyslipidemia within different sub-groups 
in the study 
 TC  
>200 
N (%) 
P 
value 
TGL  
>150 
N (%) 
P 
value 
HDL 
< 40 
N (%) 
P 
value 
LDL 
 >130 
N (%) 
P 
value 
Boys 3 
(2.9%)  
  
0.68 
35  
(34.3%) 
 
0.68 
79 
(77.5%)  
 
0.58 
4 
(3.9%)  
 
0.74 
Girls 2 
(2.0%)  
31  
(31.6%) 
79 
(80.6%)  
3 
(3.1%)  
Age  
≥ 8 years 
1 
(0.9%)  
 
0.8 
40 
(34.8%)  
 
0.53 
89 
(77.4%)  
 
0.52 
4 
(3.5%)  
 
0.98 
< 8 years 4 
(4.7%)  
26 
(30.6%) 
69 
(81.2%)  
3 
(3.5%)  
Viral load  
≥150000 
1 
(1.2%)  
 
0.35 
34 
(42.5%)  
 
0.01 
74 
(92.5%) 
 
0.000 
2 
(2.5%)  
 
0.52 
< 150000 4 
(3.4%)  
31 
(26%)  
83 
(69.7%)  
5 
(4.2%)  
 
Dyslipidemia did not differ in subcategories of wasting (>-2SD for WHZ) or 
stunting (>-2SD for HAZ), while underweight children showed a higher level of 
serum triglycerides.  
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Table 22b:  Proportion of children with dyslipidemia within different sub-groups 
based on growth pattern 
 
 TC > 
200 
N (%) 
P 
value 
TGL > 
150 
N (%) 
P 
value 
HDL < 
40 
N (%) 
P 
value 
LDL > 
130 
N (%) 
P 
value 
WHZ   
>-2SD 
3 
(2.4%) 
 
0.60 
36 
(29.3%) 
 
0.21 
 
23 
(18.7%) 
 
0.98 
4 
(3.3%) 
 
0.65 
≤ -2SD 2 
(4.7%) 
17 
(39.5%) 
8 
(18.6%) 
2 
(4.7%) 
HAZ  
>-2SD 
1 
(1.1%) 
 
0.39 
29 
(33.3%) 
 
0.93 
18 
(20.7%) 
 
0.92 
2 
(2.3%) 
 
0.42 
≤ -2SD 4 
(3.5%) 
37 
(32.7%) 
24 
(21.2%) 
5 
(4.4%) 
WAZ  
>-2SD 
1 
(1.3%) 
 
0.65 
17 
(22.4%) 
 
0.01 
21 
(27.6%) 
 
0.07 
2 
(2.6%) 
 
0.71 
≤ -2SD 4 
(3.2%) 
49 
(39.5%) 
21 
(16.9%) 
5 
(4.0%) 
 
No significant association was found between dietary intake of macronutrients 
and serum lipid levels, except in girls >9 years of age. Among girls >9 years of age 
with abnormal serum TGL, a significantly higher intake of dietary fat was observed as 
compared to girls with normal serum TGL levels [34 (19) vs 24 (12) mg/dl, 
p=0.04](Figure 13). Girls >9 years of age with abnormal serum TGL, had 
significantly higher intake of dietary fat as compared to girls with normal serum TGL 
levels [34 vs 24 mg/dl, p=0.03] (Figure 14).  
The study also looked for an association between disease severity and 
nutritional status in the presence of abnormal lipid levels during the pre-ART period. 
The variables included in the regression analysis were gender, age, weight for age Z-
score (WAZ), height for age Z-score (HAZ), weight for height Z-score (WHZ), HIV-
1  RNA level, CD4 percentage and CD4 cell count. In the univariate analysis, having 
a viral load >5.1 log10 copies/ml was associated with hypertriglyceridemia (OR 2.09, 
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95%CI 1.2-3.8, p=0.01), and hypo HDL-cholesterolemia (OR 0.18, 95% CI 0.07-0.46, 
p=0.01) (Table 23a). Similarly, underweight and stunting in children was associated 
with higher odds of having insulin resistance based on HOMA IR and C–reactive 
protein in the risk range for metabolic syndrome. 
 
Table 23a: Association of clinical characteristics with dyslipidemia by logistic 
regression  
 Univariate Multivariate 
Crude 
OR 
95% CI 
P 
value 
Adjusted  
OR 
95% CI P value 
TGL > 150 mg/dl 
Male vs Female 1.13 0.63-2.04 0.68 1.04 0.47-2.28 0.93 
Age 1.21 0.66-2.20 0.53 1.38 0.60-3.17 0.44 
WAZ < -2 SD 0.44 0.23-0.84 0.01 4.03 1.27-12.78 0.02 
HAZ < -2 SD 1.03 0.56-1.86 0.93 0.47 0.17-1.31 0.15 
WHZ < -2SD 0.63 0.31-1.31 0.21 1.04 0.38-2.82 0.93 
CD4 cell ct 0.72 0.39-1.34 0.11 0.85 0.29-2.45 0.76 
Viral load < 
15000 
2.09 1.15-3.84 0.01 0.28 0.01-5.72 0.41 
LDL chol > 130 
Male vs Female 1.29 0.28-5.93 0.74 3.46 0.23-52.1 0.37 
Age 0.98 0.21-4.52 0.98 3.10 0.19-49.25 0.42 
WAZ < -2 SD 0.64 0.12-3.40 0.71 0.02 0.00-6.57 0.18 
HAZ < -2 SD 0.51 0.09-2.68 0.42 8.05 0.46-140 0.15 
WHZ < -2SD 0.68 0.12-3.90 0.65 27.61 0.11-642 0.23 
CD4 cell ct 1.24 0.23-6.57  E 0.24-E E 
Viral load 0.58 0.11-3.09 0.52 E 0.12-E 1.00 
HDl-c < 40 mg/dl 
Male vs Female 1.21 0.61-2.39 0.58 1.09 0.44-2.70 0.85 
Age 1.26 0.63-2.53 0.52 0.95 0.37-2.49 0.92 
WAZ < -2 SD 1.87 0.94-3.72 0.07 0.14 0.04-0.52 0.03 
HAZ < -2 SD 0.96 0.48-1.92 0.92 6.32 1.92-20.75 0.002 
WHZ < -2SD 1.01 0.41-2.45 0.98 3.41 0.98-11.89 0.05 
CD4 cell ct 1.29 0.62-2.74  0.48 0.13-1.68 025 
Viral load 0.18 0.07-0.46 0.000 0.21 0.01-4.42 0.32 
TC > 200 mg/dl 
Male vs Female 1.45 0.24-8.89 0.68 1.92 0.14-26.79 0.63 
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Age 0.18 0.02-1.62 0.8 0.46 0.03-6.44 0.57 
WAZ < -2 SD 0.40 0.04-3.65 0.65 0.34 0.02-6.84 0.48 
HAZ < -2 SD 0.32 0.03-2.8 0.39 E E 0.99 
WHZ < -2SD 0.51 0.08-3.17 0.6 3.53 0.17-71.26 0.52 
CD4 cell ct 2.00 0.22-18.26  0.00 0.00-E 0.99 
Viral load 0.36 0.04-3.32 0.35 1.600 0.01-E 1.00 
 
In the multivariate logistic regression model, adjusting for age and gender, it 
was found that children who were  
(i) Moderately to severely underweight [aOR 4.03 (95% CI 1.27-12.78), 
p=0.02] had higher odds of abnormal triglyceride levels at baseline  
(ii) Moderately to severely stunting [aOR 6.32 (95% CI 1.92-20.75), 
p=0.002] and wasting [aOR 3.41 (95% CI 0.98-11.89), p=0.05] had 
higher odds of low HDL-cholesterol levels at baseline  
In the Multiple Logistic regression models used to assess the relationship of 
gender, age, weight for age Z-score (WAZ), height for age Z-score (HAZ), weight for 
height Z-score (WHZ), HIV RNA levels with Insulin Resistance, it was found that  
(i) Moderately to severely stunted (HAZ <-2SD) had higher odds of 
having abnormal insulin resistance [aOR 10.08 (95% CI 1.5, 68.7), 
p=0.02] at baseline, while children who were underweight had lesser 
chances of having insulin resistance at baseline. 
Table 23b: Association of clinical characteristics with insulin resistance by 
logistic regression  
 Adjusted OR P value 
95% CI 
Lower Upper 
 
Male vs Female .422 .300 .082 2.161 
Age .693 .663 .133 3.609 
HAZ < -2 SD 10.080 .018 1.479 68.678 
WAZ < -2 SD .049 .012 .005 .508 
WHZ < -2SD 2.125 .584 .143 31.596 
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5.9 STUDY OUTCOME AFTER 24 MONTHS OF ART INITIATION 
After ART initiation, the study followed up the children every 3 months with 
anthropometric measurements, and every 6 months with a blood draw, to assess 
disease progression and metabolic changes. At the end of 12 months of ART, 180 
(90%) children were on follow-up. At end of 24 months, 163 children (82%) were 
available for evaluation while 37 children were lost to follow-up due to various 
reasons [migrated to native place (19), death (15) and missed visit (3)]. Self-reported 
adherence to ART at 24 months of ART was >90% in 83% of children, 80-90% in 7% 
and < 80% in 10% of children on ART. These percentages were almost identical to 
those after 12 months of ART. 
 
(i) Disease Severity and progression: There was significant improvement in 
disease state during follow-up, as can be seen from the table 24 below. The majority 
of the children had an undetectable viral load - 72% and 69% of the children at the 
12
th
 and 24
th
 month respectively. 
Their immunologic response was also good. Among children > 5years of age, 
90% had an increase in their absolute CD4+ T cell count to over 350 cells/mm
3
 at 24 
months of follow-up (Table 24).  
 
 
CD4 cell ct 2.371 .500 .193 29.064 
Viral load 
18924540.61
4 
1.000 .000 . 
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Table 24: CD4 cell recovery wile on ART 
CD4 cell count 
(above 5 years) 
Baseline 
N  (%) 
12 months 
N (%) 
24 months 
N (%) 
P value 
≥ 350 cells/mm3 88 (59.5) 124 (90.5) 116 (91.3) 
0.00 
< 350 cells /mm
3
 60 (40.5) 13 (9.5) 11 (8.7) 
 
In children < 5 years of age, 70% showed immunologic recovery at 24 months 
of ART with CD4+ T cell percentage >25%. In children who responded to treatment, 
it was observed that as the duration of ART increased, there was a significant log 
reduction in HIV-1 viral load and a concurrent increase in CD4 cell count, as shown 
in the graph in Figure 13. 
 
Table 25: Disease progression through 24 months of ART 
 
Characters 
 
Baseline 12 Months 24 months 
P  
value 
Mean (SD) 
Hemoglobin 
(g/dl)  
10.8 (1.5) 11.7 (1.3) 11.8 (1.3) 0.00 
Platelets 
(cells/mm
3
)
 
301357 (10505) 340889 (9046) 278695 (11883) 0.14 
Median (IQR) 
CD4  count 
cells /mm
3
 
451 
(290 - 692) 
837 
(589 - 10187) 
914 
(629 - 1176) 
0.00 
Viral load 
copies/ml 
105000 
(16022 - 315246) 
55 
(20 - 2200) 
32 
(20 - 34.05) 
 
0.00 
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Figure 14: Relationship between dietary intake and lipid levels in girls 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Concordance between viral load and CD4 cell count while on ART 
shown in logarithmic scale 
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A proportion of the children failed to respond to ART and developed 
virological and immunological failure while on ART. Immunologic failure was 
defined as a decrease in CD4 cell count of > 30% from baseline; and virologic failure 
was defined as HIV-1 RNA of >1,000 copies/ml at 12 and 24 months after ART 
initiation. Failure occurred most in children between 6-12 months on ART, and 
tended to be more among those between the age group of 7-12 years.  There was a 
trend towards more virologic failure among children receiving nevirapine-based ART 
as compared to efavirenz-based ART. 62% of children with virologic failure reported 
>90% of adherence to ART.  
 
A significant discordance was also noticed between virological and 
immunological failures. Table 26 shows that after 12 months of ART, there were 
almost 29% of children who had viral load of more than 1000 copies /ml, indicating 
virological failure. However, only 8% of these children showed a concurrent fall in 
CD4 cell count. 
 
Table 26: Proportion of children with immunological and virological failure 
Characters 
(median, IQR) 
Baseline 12 Months 24 months P value 
Immunologic failure 66 (33) 15 (8.3) 11 (6.7) 0.00 
Virologic failure 
(VL >1000 copies/ml) 
186 (93.5) 51 (28.5) 50 (30.3) 0.00 
 
Among the 51 children (29 girls and 21 boys) with virologic failure, only two 
showed immunologic failure; there was no correlation between virologic and 
immunologic failure. At 12 months, of the 51 children with virologic failure, 43 
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children showed drug-resistant mutations while 7 children did not show any 
amplification. Multiple NNRTI-associated mutations including K103N (33%), Y181C 
(28%), G190A/S, Y188C/L and V106M/A and L100I were observed in these children 
at the time of virologic failure, as were some M184V and thymidine analog mutations 
(TAMs). 
(ii) Body shape changes: The study children were examined for 
anthropometric and body shape changes at three monthly intervals. Height-for-age Z-
score and weight-for-age z-scores were derived and compared to their baseline values. 
Outcomes for HIV infected children developing body shape changes (fat atrophy and 
central fat deposition) included changes in the following parameters from baseline to 
24 months (Table 27). 
 1. Body mass index (BMI) 
 2. Mid-arm circumference (MAC) 
3. Height-for-age Z-scores  
4. Weight-for-age and weight-for-height Z-scores 
Table 27: Changes in anthropometric measure with time while on ART 
Characters Baseline 12 Months 24 months P value 
BMI (kg/m
2
) 14.03 ± 1.86 14.54 ± 1.76 14.86 ± 1.74 0.00 
Mid-arm  
circumference 
15.3 ± 2.2 16.6 ± 2.2 17.4 ± 2.5 0.00 
 
HAZ-score 
(median, IQR) 
 
-2.21 
[(-3.08) - (-0.2)] 
-0.9 
[(-2.1) - (0.1)] 
-0.07 
[(-0.9) - (1.1)] 
0.00 
 
WAZ-score 
(median, IQR) 
 
-2.3 
[(-2.9) - (-1.6)] 
-1.4 
[(-2.02)-(-0.3)] 
-0.6 
[(-1.3) - (0.4)] 
0.00 
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WHZ-score 
(median, IQR) 
 
-1.3 
[(-2.03) - (-0.4)] 
-0.9 
[(-1.6) - (-0.2)] 
-1.1 
[(-1.6) - (-0.3)] 
0.00 
 
 
After 24 months of ART, as shown in Table 28, a significant improvements 
were noticed in the weight-for-age and height-for-age z-scores from baseline (all 
p<0.001). Moreover, the proportion of children who remained stunted and 
underweight after 2 years on ART was reduced considerably from the ART naïve 
period in the same cohort. Nonetheless, 6% of the children remained stunted (HAZ-
score < -2) and 9% were undernourished for their age (WAZ-score < -2) (Table 28a).  
Catch-up growth in terms of age-related-height and weight was evident after initiation 
of ART (Figures 16 and 17). 
 
Table 28a: Proportion of children with age-related Z-scores while on ART 
Characters 
Baseline 
N (%) 
12 Months 
N (%) 
24 months 
N (%) 
P value 
HAZ-score <-2SD 
 
113(56.5) 40(26) 9(6.3) 0.000 
WAZ-score  <-2SD 
 
124(62) 40(26) 13(9.2) 0.000 
WHZ-score <-2SD 
 
43(25.9) 18(2.7) 14(12.7) 0.002 
 
Gender-wise scores: The study examined the gender-wise break-up of the 
age-related height and weight changes with ART. Both genders showed a uniform 
improvement in age-related height and weight z-scores over 2 years of ART. Table 
28b shows proportion of girls and boys with HAZ, WAZ and WHZ less than -2SD of 
their age related scores. 
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Table 28b: Gender wise proportion of age-related Z-scores while on ART 
(i) Girls 
Characters 
Baseline 
N (%) 
12 Months 
N (%) 
24 months 
N (%) 
P value 
HAZ-score <-2SD 
 
55(56.1) 19(25.0) 4(5.6) 0.000 
WAZ-score  <-2SD 
 
58(59.2) 19(24.7) 6(8.3) 0.000 
WHZ-score <-2SD 
 
22(26.8) 10(13.7) 8(14.8) 0.05 
 
(ii) Boys 
Characters 
Baseline 
N (%) 
12 Months 
N (%) 
24 months 
N (%) 
P value 
HAZ-score <-2SD 
 
58(56.9) 21(26.9) 5(7.1) 0.000 
WAZ-score  <-2SD 
 
66(64.7) 21(27.3) 7(10.0) 0.000 
WHZ-score <-2SD 
 
21(25.0) 8(11.6) 6(10.7) 0.02 
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Figure 16 : Number of children who remained stunted after ART initiation  
 
 
 
Figure 17 : Number of Children who remain underweight after ART initiation  
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Figure 18a: Changes in age-related Z-scores <-2SD in girls on ART 
 
 
 
 
Figure 18b: Change in age-related Z-scores <-2SD in boys on ART 
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Development of peripheral fat atrophy and/or central fat deposition 
Fat deposition was defined by objective measure as having a waist 
circumference-for-age percentile greater than the percentile for weight-for-age or 
BMI. 
Fat atrophy was defined as having a MAC-for-age percentile less than their 
weight-for-age or BMI percentile. Table 29a and 29b show that at baseline 72% of 
children had a lower MAC-for-age Z-score, while after 24 months of ART this 
decreased to none. 
Fat atrophy: having a MAC-for-age percentile less than the subject’s weight-
for-age or BMI percentile. The table shows that at baseline 28% of the children had a 
lower MAC-for-age Z-score than recommended. 
 
Table 29a: Comparison of MAC-for-age Z-scores versus WAZ at baseline 
Characters 
MAC Z-scores 
>-2.00 <=-1.99 
WAZ-score  <-2SD 8 (27.6%) 21 (72%) 
WAZ-score  >-2SD 
 
11 (84.6%) 2 (15.4%) 
 P = 0.001 
 
Table 29b: Comparison of MAC-for-age Z-scores versus WAZ at 24 months of 
ART 
Characters MAC Z-scores 
 >-2.00 <=-1.99 
WAZ-score  <-2SD 
 
2(100%) 0(0%) 
WAZ-score  >-2SD 19(90.5%) 2(9.5%) 
P=Not significant 
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(iii) Metabolic abnormalities: Study outcomes for HIV-infected children 
with metabolic abnormalities while on ART included changes in the following 
parameters from baseline to 24 months. 
(i) Dyslipidemia: a) Fasting serum total cholesterol, LDL-cholesterol, HDL-
cholesterol     b) Fasting serum triglyceride 
Table 30a: Changes in serum lipid parameters while on ART 
Serum Lipid Levels  
(mean + SD) 
Baseline  
 
12 Months  24 months  P  
value 
Total Cholesterol mg/dl 134 ± 34.2 159.3 ± 32.4 156.7 ± 28.6 0.00 
Triglycerides mg/dl  136.4 ± 73.0 97.4 ± 41.5 94.1 ± 48.6 0.00 
HDL-c mg/dl  31.4 ± 10.2 48.7 ± 13.9 48.8 ± 13.4 0.00 
LDL-c mg/dl  75.1 ± 29.8 91.2 ± 27.5 89.1 ± 23.5 0.00 
Total cholesterol / HDL-c ratio 4.5 ± 1.3 3.4 ± 1.0 3.5 ± 1.4 0.00 
 
 
By 24 months of ART, the measure of mean HDL-cholesterol below the 
normal range prior to ART improved, normal HDL-c was restored, and serum 
triglycerides were reduced (Table 30a). A trend towards increasing mean serum total 
cholesterol levels also manifested over 24 months. The graph below outlines the 
changes in the lipid parameters over time following initiation of ART. 
 
 
(ii) Glucose intolerance:   a) Fasting serum glucose 
                          b) Fasting serum insulin 
There was a significant change in the serum insulin levels and HOMA-IR 
score over time with the initiation of ART. Such increase in serum insulin levels with 
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ART has also been noticed in other cohort on ART over time. C-reactive protein, a 
marker of inflammation as well as a predictor for cardiovascular disease risk, declined 
over time with use of ART, though this change remained statistically non-significant 
(Table 30b). 
 
Table 30b: Changes in Blood glucose and insulin levels with ART 
Characteristics  
(mg/dl) 
Baseline  
(n=200) 
12 Months 
(n=176) 
24 months 
(n=113) 
P  
value 
Blood glucose   
(mean ± SD) 
82.2 ± 10.4 81.9 ± 10.6 83.9 ± 9.8 0.06 
Serum Insulin  
Median ( IQR) 
2.7 (1.6 - 5.6) 3.7 (2.2 - 6.4) 4.4 (2.3 - 7.9) 0.04 
HOMA –IR 0.53 (0.3 - 1.2) 0.8 (0.4 - 1.3) 0.9 (0.5 - 1.6) 0.01 
 
C-reactive protein  
median (IQR)) 
2 (0.6 - 7.2) 1.7 (0.6 - 7.1) 1.2 (0.6 - 5.4) 0.81 
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Figure 19:  Changes in the mean blood lipid parameters while on ART 
 
 
 
Figure 20: Changes in mean Serum insulin and HOMA-IR while on ART 
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(iv) Comparison with Non-HIV infected children as controls 
 The mean value of serum lipid and insulin levels of ART naïve HIV infected 
children was compared with non-HIV infected children of the same age group. HIV 
infected children had significantly higher levels of serum triglycerides, low levels of 
HDL-c and LDL-c as compared to the non-HIV infected children. This shows the 
effect of HIV disease per se on serum lipid levels. Also in the table below, effect of 
12 months of ART on serum lipid and insulin levels are shown. There is a significant 
change in values after 12 month of ART (Table 31a).   
 
Table 31a: Comparison of lipid levels between Non-HIV and HIV infected 
children  
Serum Lipid 
Levels 
(mean ± SD) 
Non HIV infected 
Controls 
(n=59) 
HIV infected 
P 
value Before Art 
initiation 
After 12 months 
of ART 
Total Cholesterol 
mg/dl 
136.64 ± 18.32 134 ± 34.2 159.3 ± 32.4 0.41 
Triglycerides 
mg/dl 
72.73 ± 29.14 136.4 ± 73.0 97.4 ± 41.5 0.000 
HDL-c mg/dl 37.63 ± 3.99 31.4 ± 10.2 48.7 ± 13.9 0.000 
LDL-c mg/dl 87.19 ± 13.69 75.1 ± 29.8 91.2 ± 27.5 0.000 
Blood glucose 86.51 ± 6.86 82.2 ± 10.4 81.9 ± 10.6 0.000 
Serum Insulin 4.04 ± 3.25 5.3 ± 6.6 5.6 ± 7.6 0.99 
HOMA –IR 0.86 ± 0.69 1.1 ± 1.5 1.2 ± 1.9 0.005 
CRP 1.67 ± 0.89 3.7±3.7 3.7±3.8 0.000 
 
On gender-wise comparison of serum lipid levels with their non-HIV 
counterparts, changes in lipid were seen in both girls and boys, while HOMA IR was 
significantly high among the HIV infected boys as compared to their non-HIV 
counterpart. (Table 31b )  
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The serum lipid levels were also compared between HIV infected children on 
ART and those not on ART at the end of 12 months of follow-up (Table 32). At the 
end of 12 months, the group of HIV infected children on ART had significantly high 
level of HDL-c while the HIV infected children not on ART continued to have low 
levels of HDL-c.  
 
Table 31b: Gender wise comparison between controls and HIV infected children 
on  ART  
Serum Lipid  
Levels (mg/dl) 
(mean + SD) 
Boys Girls 
Non HIV HIV 
P  
value 
Non HIV HIV 
P  
value 
Total  
Cholesterol 
134.9 ± 20 131.9±34.8 0.99 138.9 ± 14 136.2±33.7 0.43 
Triglycerides 77.2 ± 33.8 135.9±71.7 0.06 66.5 ± 20.2 136.8±74.8 0.000 
HDL-c mg/dl 37.8 ± 4.1 31.5±9.6 0.000 37.2 ± 3.8 31.2±10.7 0.000 
LDL-c mg/dl 85.1 ± 15.6 73.3±31.1 0.000 89.9 ± 10.1 76.9±28.4 0.000 
Blood glucose 85.8 ± 6.9 82.3±11.1 0.002 87.4 ± 6.7 82.0±9.6 0.000 
Serum Insulin 3.18 ± 2.92 5.3±7.5 0.92 5.2 + 3.37 5.3±5.6 0.82 
HOMA –IR 0.67 ± 0.61 1.1±1.7 0.003 1.12 +0.72 1.1±1.2 0.93 
 
The serum lipid levels were also compared between HIV infected children on 
ART and those not on ART at the end of 12 months of follow-up (Table 32). At the 
end of 12 months, the group of HIV infected children on ART had significantly high 
level of HDL-c while the HIV infected children not on ART continued to have low 
levels of HDL-c.  
Similarly HIV infected children not on ART had a high level of serum 
triglyceride in comparison with those on ART and the non-HIV infected children. 
This confirms the claim that HIV disease per se increases the serum triglyceride levels 
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and is a marker for disease severity, while with ART the levels return to normal 
levels. 
 
Table 32: Comparison between HIV infected children with and without ART  
Serum Lipid Levels  
(mean + SD) 
At end of 12 months of follow-up                              
HIV infected children P  
value Not on ART 
(n=27) 
On ART 
(n=180) 
Total Cholesterol 107.7 ± 25.8 159.3 ± 32.4 0.000 
Triglycerides mg/dl 117.4 ± 57.6 97.4 ± 41.5 0.000 
HDL-c mg/dl 37.8 ± 9.0 48.7 ± 13.9 0.000 
LDL-c mg/dl 80.2 ± 27.3 91.2 ± 27.5 0.000 
Blood glucose 79.1 ± 12.1 81.9 ± 10.6 0.000 
 
 
(v) Proportion of Children with Metabolic abnormalities  
(i) Dyslipidemia: The proportion of children who had blood lipid levels above 
the upper limit of normal at the baseline before ART initiation, and subsequently at 12 
months and 24 months after ART initiation was estimated and compared the data 
using chi-square test. For this analysis, the cut-off levels for abnormal lipids were 
defined as follows: hypertriglyceridemia as TGL>150mg/dl, hypercholesterolemia as 
TC> 200 mg/dl (borderline elevation if TC between 170-199mg/dl), LDL-c >130 
mg/dl and HDL-c <40mg/dl. Table 33a shows the proportion of children with 
abnormal lipid levels at various time points. 
While the proportion of children with hypercholesterolemia at 12 months of 
ART showed an increase from baseline, subsequently at 24 months of ART no further 
increase was noticed. The number of children with low HDL-c reduced considerably 
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at 12 months of ART.  Any dyslipidemia, defined as serum triglyceride >150 or LDL-
cholesterol >130 or total cholesterol >200 mg/dl at 24 months of ART was seen in 
20% (32/163) of children. 
(ii) Glucose Intolerance: The proportion of children who had serum insulin 
levels above the upper limit of normal at baseline before ART initiation, and 
subsequently at 12 months and 24 months after ART initiation. For this analysis, 
HOMA IR cut-off point for diagnosis of insulin resistance in children was taken as  
> 3.5. Though not statistically significant, there was an increase in the number of 
children showing insulin resistance by the end of 24 months of ART.  WHR ratio of 
0.9 in boys and 0.8 in girls was taken as cut-off, which showed a significant increase 
in both the groups by the end of 24 months of ART (Table 33b).   
 
Table 33a: Proportion of children with Lipid levels above normal at baseline and 
during ART 
Abnormal serum 
lipid levels (mg/dl) 
Proportion of 
children at 
baseline  
n (%) 
Proportion 
of children 
at 12 months  
n (%) 
Proportion of 
children at 24 
months  
n (%) 
P  
value 
Total  
Cholesterol > 200 
5 (2.5) 15 (7.5) 8 (4.9) 0.24 
LDL  
cholesterol > 130 
7 (3.5) 12 (6.7) 6 (3.7) 0.92 
HDL  
cholesterol < 35 
130 (65.0) 24 (13.3) 21(12.9) 0.00 
HDL  
cholesterol < 40 
158 (79.0) 40 (22.2) 38 (23.3) 0.00 
Triglyceride > 150 66 (33.0) 22 (12.2) 18 (11.0) 
0.00 
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Table 33b: Proportion of children with blood glucose and insulin levels above 
normal at baseline and during ART 
 
Variables 
(mg/dl) 
Proportion of 
children at 
baseline n (%) 
Proportion of 
children at 12 
months n (%) 
Proportion of 
children at 24 
months n (%) 
P 
value 
Glucose  
> 100 
8(4.1) 8(4.5) 10(6.2) 0.39 
Serum insulin 165 (83.3) 144 (81.8) 93 (75.6) 
 
0.10 
 
HOMA-IR  
>3.5 
13(6.7) 9(5.1) 11(9.1) 0.54 
hs-CRP 3-10 75(37.9) 71(40.3) 45 (36.6) 
 
0.89 
 
Waist : Hip 
ratio > 0.9 
(for Boys) 
9 (8.8) 20 (23.5) 15 (22.1) 0.01 
Waist : Hip 
ratio > 0.8 
(for girls) 
1(1.0) 2(2.2) 3(4.2) 0.17 
 
Children with dyslipidemia were further categorized based on various factors 
like age, gender, presence of stunting or underweight and viral load at baseline in the 
pre-ART period. Viral load at baseline had an effect on the 24 month HDL-c levels 
(Table 34).  
As there was a significant increase in waist: hip ratio, we looked for 
correlation between serum insulin and body mass index in these children during the 
pre-ART and at 24 months after ART. Though the correlation coefficient was higher 
with ART than the ART naïve period, in general only a poor correlation was noticed 
between serum insulin and body mass index in the cohort (Figure 21a & b). 
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Figure 21: Proportion of children showing changes in serum lipid, glucose and 
insulin levels while on ART 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Figure 22a : Graph showing correlation between serum insulin levels and body 
mass index pre ART  
 
Figure 22b: Graph showing correlation between serum insulin levels and body 
mass index 24 months after ART 
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Table 34: Number children with dyslipidemia at 24 months under different sub 
groups  
 
 
TC 
> 
200 
N 
 
P 
value 
 
TGL  
> 150 
N (%) 
 
P 
value 
 
HDL  
< 40 
N 
(%) 
 
P 
value 
 
LDL  
>130 
N 
 
P 
value 
 
HOMA-
IR   
>3.5 
 
P 
value 
 
WAZ  
>-2SD 
at 
Baseline 
3 
1.00 
8 
(11.9) 
0.76 
14 
(20.9) 
0.54 
1 
0.21 
5 
 
0.86 
=<-2SD 5 
10 
(10.4) 
24 
(25.0) 
5 6 
HAZ at 
baseline 
>-2SD 
3 
0.73 
7 
(9.6) 
0.59 
17 
(23.3) 
0.99 
2 
0.69 
5 
 
0.95 
=<-2SD 5 
11 
(12.2) 
21 
(23.3) 
4 6 
WHZ at 
baseline 
>-2SD 
5 
0.67 
13 
(12.5) 0.76 
23 
(22.1) 0.73 
3 
0.33 
9 
0.19 
=<-2SD 2 3(9.4) 8(25) 2 0 
Boys 3 
0.720 
8(10) 
0.67 
18 
(22.5) 
0.81 
2 
0.42 
4 
0.53 
Girls 5 10(12) 
20 
(24.1) 
4 7 
Age  
> 8 years 
5 
1.00 
11 
(11.5) 
0.84 
20 
(20.8) 
0.37 
3 
0.69 
9 
0.19 
< 8 years 3 7(10.4) 
18 
(26.9) 
3 2 
Viral load 
at 
baseline 
>150000 
6 
0.05 
8 
(13.3) 
0.47 
 
 
4 
0.19 
7 
0.05 
< 150000 2 
10 
(9.7) 
 2 4 
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At 24 
months 
 
TC 
> 
200 
N 
 
P 
value 
 
 
TGL 
> 150 
N 
(%) 
 
P 
value 
 
 
HDL 
< 40 
N 
(%) 
 
P 
value 
 
 
LDL 
> 
130 
N 
 
P 
value 
 
 
HOMA-
IR  >3.5 
 
 
P 
value 
 
Viral load 
at 24 
month 
>150000 
0 
1.00 
1 
(25) 
0.37 
4 
(100) 
 
0 
1.00 
0 
1.00 
< 150000 8 
17 
(10.7) 
34 
(21) 
6 11 
WAZ  >-
2SD at 24 
month 
7 
0.55 
15 
(11.8) 
0.36 
28 
(22) 
1.00 
4 
0.39 
11 
1.00 
=<-2SD 1 
0 
(0) 
3 
(23.1) 
1 0 
HAZ at 24 
month 
>-2SD 
8 
1.00 
15 
(11.5) 
0.59 
29 
(22.1) 
1.00 
5 
1.00 
11 
0.59 
=<-2SD 0 
0 
(0) 
2 
(22.2) 
0 0 
WHZ at 
24 months 
>-2SD 
6 
1.00 
12 
(12.8) 
0.36 
21 
(22.3) 
1.00 
5 
1.00 
6 
1.00 
=<-2SD 0 
0 
(0) 
3 
(21.4) 
0 1 
MAC at 
24 month 
<115mm 
0 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
>115mm - - 
17 
(12.2) 
- 
32 
(23) 
- 5 - 11 - 
ART 
regimen 
ZLN/ZLE 
3 
0.03 
12 
0.15 
27 
0.41 
1 
0.02 
6 
0.29 
SLN/SLE 4 6 5 3 4 
Food 
secure 
1 
0.06 
9 
0.18 
15 
0.82 
1 
0.17 
8 
0.05 
Food 
Insecure 
7 6 18 5 3 
Visible 
Fat>30 
(gm/day) 
7 
0.06 
8 
0.71 
16 
0.86 
5 
0.05 
6 
0.28 
FAT<30 1 9 16 0 2 
APOA5 
Wild 
3 
0.12 
8 
0.04 
22 
0.24 
1 
0.02 
6 
0.21 
Carrier 5 10 16 5 5 
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Any dyslipidemia (defined as TC >200 or LDL >130 or TGL >150 or HDL-c 
<35) after 24 months of ART was seen in 53 of 163 (33%) HIV infected children on 
follow-up. This change was evident among children with high viral load at baseline, 
initiated on a stavudine containing regimen, with a higher fat intake in the diet.   
 
5.10 Predictors of Dyslipidemia 
 Various clinical and laboratory parameters both at baseline and 24 months 
after ART were checked for correlation with dyslipidemia. ART regimen, especially 
stavudine based regimen and increased intake of dietary fat were significantly 
associated with increased chances of having high blood total cholesterol and LDL- 
cholesterol after 24 months of ART. 
Age of the child at the time of ART initiation, CD4 cell count and viral load 
both at the time of ART initiation and at 24 months, gender, nutritional status, type of 
ART, food security of household, adherence to ART, gene polymorphism, dietary 
intake of fat etc., were tested in the logistic regression model to determine predictors 
of dyslipidemia while on ART. Though a significant association was noticed in the 
univariate model with various factors like viral load at baseline, nutritional status etc., 
none of them showed any significant association when tested in the multivariate 
model, except gene polymorphism and HDL-c. Children with polymorphism in the 
APOA5 gene had a higher chance of having lower cholesterol while on ART [OR = 
2.44, 95% CI (1.16 – 5.12)], p=0.02, while those who had the carrier allele (C) had 
higher mean TGL levels (165 mgs/dl) as compared to the wild type (138 mgs/dl). 
Girls had higher TGL levels as compared to boys. Also it was noticed that children 
from food insecure households had a lesser chance of developing insulin resistance by 
HOMA IR [OR = 0.27, 95% CI 0.07 – 1.09)], p=0.07. 
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MANOVA test by General Linear Model (GLM) was performed to explore 
the possibility of multiple risk factors influencing the outcomes in an individual. First 
when MANOVA was applied to look for interaction between genes and ART regimen 
(with type of NRTI) on dyslipidemia in the presence of different variables like viral 
load (VL), food security (FS), underweight (WAZ) and wasting (WHZ), we found 
that underweight (WAZ) and wasting (WHZ) had a significant effect on total 
cholesterol and LDL-c levels in the presence of specific type of ART regimen and 
wild type gene polymorphism (Table 35). 
 
Table 35: MANOVA model showing the interaction between gene, ART regimen 
and dyslipidemia  
At 24 months APOA5 ART Mean SD P value 
VL FS WAZ WHZ 
Total 
Cholesterol 
Wild(TT+GG) 
Zido 153.59 25.2 
0.09 0.42 0.005 0.01 
Stavu 171.55 33.4 
Others 154.08 34.3 
Carrier(Others) 
Zido 159.33 30.6 
Stavu 151.57 36.0 
Others 160.50 9.1 
HDL-c 
Wild(TT+GG) 
Zido 49.34 13.9 
0.30 0.90 0.28 0.19 
Stavu 51.10 15.6 
Others 44.62 12.4 
Carrier(Others) 
Zido 49.07 8.2 
Stavu 47.00 11.0 
Others 60.50 2.1 
Triglyceride 
Wild(TT+GG) 
Zido 88.87 46.7 
0.24 0.36 0.35 0.74 
Stavu 108.95 57.5 
Others 95.54 23.1 
Carrier(Others) 
Zido 102.60 42.5 
Stavu 111.57 67.0 
Others 101.50 7.7 
LDL-c 
Wild(TT+GG) 
Zido 86.54 21.9 
0.39 0.19 0.02 0.03 
Stavu 98.65 25.7 
Others 90.31 25.0 
Carrier(Others) 
Zido 89.80 23.7 
Stavu 82.29 41.6 
Others 80.00 5.6 
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Next we used the MANOVA model to analyze the interaction between gene, 
ART regimen (type of NRTI) and dietary intake of fat on dyslipidemia and found that 
underweight (WAZ) and wasting (WHZ) had a significant effect on total cholesterol 
and LDL-c levels in the presence of specific type of ART regimen and wild type gene 
polymorphism (Table 27).  
 
Table 36: MANOVA model showing the interaction between gene, ART regimen, 
diet and dyslipidemia  
At 24 
months 
APOA5 ART Mean SD P value 
Total 
Cholesterol 
Wild 
(TT+GG) 
Zido 
<=30 152.06 26.6 VL FS WAZ WHZ 
>30 157.25 25.2 
0.13 0.78 0.01 0.01 
Stavu 
<=30 187.22 33.6 
>30 152.78 28.2 
Others 
<=30 140.83 45.9 
>30 167.50 17.2 
Carrier 
(Others) 
Zido 
<=30 159.11 35.0 
>30 155.60 26.5 
Stavu 
<=30 166.25 31.9 
>30 132.00 37.0 
Others 
<=30 154.00 
 
>30 167.00 
 
HDL-c 
Wild 
(TT+GG) 
Zido 
<=30 49.72 11.9 
0.26 0.55 0.56 0.34 
>30 51.54 16.5 
Stavu 
<=30 53.67 9.7 
>30 45.33 15.6 
Others 
<=30 41.67 15.9 
>30 44.50 6.3 
Carrier 
(Others) 
Zido 
<=30 48.44 7.9 
>30 49.40 10.5 
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Stavu 
<=30 50.00 10.8 
>30 43.00 12.1 
Others 
<=30 59.00 
 
>30 62.00 
 
Triglyceride 
Wild 
(TT+GG) 
Zido 
<=30 89.88 49.6 
0.22 0.89 0.38 0.89 
>30 85.54 45.0 
Stavu 
<=30 102.78 58.5 
>30 118.67 64.1 
Others 
<=30 92.83 12.1 
>30 102.67 31.4 
Carrier 
(Others) 
Zido 
<=30 100.44 41.7 
>30 104.00 52.8 
Stavu 
<=30 67.50 27.4 
>30 170.33 57.2 
Others 
<=30 96.00 
 
>30 107.00 
 
LDL-c 
Wild 
(TT+GG) 
Zido 
<=30 84.44 21.9 
0.49 0.46 0.02 0.01 
>30 88.67 23.2 
Stavu 
<=30 113.00 23.2 
>30 83.78 20.2 
Others 
<=30 80.67 32.1 
>30 102.33 11.8 
Carrier 
(Others) 
Zido 
<=30 90.67 25.8 
>30 85.40 23.6 
Stavu 
<=30 102.75 37.8 
>30 55.00 33.0 
Others 
<=30 76.00 
 
>30 84.00 
 
 
GLM model with diet, ART and gene polymorphism also suggested that 
besides underweight and wasting, type of NRTI in the ART regimen was also an 
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important predictor for dyslipidemia. Patients on Stavudine based regimen, inspite of 
low dietary intake of fat, in the presence of wild type gene polymorphism in the 
APOA5 gene had a significantly higher chance (p=0.03) of having increased LDL-
cholesterol after 24 months of ART. Similarly, patients on zidovudine showed an 
increase in serum total cholesterol and LDL-cholesterol when they had the wild type 
gene polymorphism and high fat intake in their diet. Also, in patients on zidovudine, 
the presence of carrier gene polymorphism irrespective of dietary fat intake, had a 
propensity to show higher triglyceride levels. 
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DISCUSSION 
 
This study aimed to determine the prevalence of HIV associated 
Lipodystrophy Syndrome in terms of dyslipidemia and glucose intolerance among 
HIV infected children between the age groups of 2 – 12 years before initiation and 2-
years after initiation of ART. In addition, the study also evaluated the development of 
metabolic complications of ART such as lipodystrophy, dyslipidemia or insulin 
resistance and identifies predictors for the development of these complications 
following the initiation of ART. The study enrolled 200 HIV infected ART-naïve 
children attending the ART clinic at the Institute of Child Health and Hospital for 
Children, Egmore, Chennai and the subcentre of the National Institute for Research in 
Tuberculosis, Chetput, Chennai. All the children underwent a set of predefined 
investigations before the initiation of ART. After the initiation of ART they were all 
followed up at periodic intervals for the next two years to assess for the development 
of ART-associated metabolic complications. 
The two hundred children enrolled in the study included equal number of girls 
and boys. Almost all had acquired the infection perinatally from mother, and most of 
them were breast fed. As most were either with a single parent or under foster-care, 
not much was known about the single dose nevirapine prophylaxis during their 
neonatal period. More than half were moderately to severely malnourished and 
stunted for their age with a high level of food insecurity within their households. The 
majority were symptomatic, and were in HIV clinical stage 3 or 4 and in an advanced 
stage of immunosuppression. All of these details highlight the late presentation of 
these HIV-infected children to the ART clinics for treatment initiation.  A similar 
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picture is seen in sub-Saharan Africa where almost 43% of children presented to the 
ART clinic for ART initiation were in stages 3 or 4 of HIV disease [80]. There is a 
need to improve measures to avoid late presentation and delay in initiating ART 
among HIV infected children in order to avoid pediatric morbidity and mortality due 
to HIV.   
The study data demonstrated that ART-naïve Indian children with moderate to 
severe immunosuppression have a high prevalence of dyslipidemia with the majority 
of the children having low HDL-c and anemia, more than one-third having high TGL, 
and almost a quarter having insulin resistance. Inflammatory marker for 
cardiovascular morbidity, CRP, was also elevated in 18% of the children in this 
cohort. The higher prevalence of hypo-HDL-cholesterolemia in this study may be 
explained by the greater severity of immunosuppression in these children (mean 
CD4% of 16%). Our findings are similar to that observed in the severely 
immunocompromised (mean CD4% of 6%) cohort of Thai children, where 94% had 
hypo-HDL cholesterolemia prior to initiation of ART [15]. Other studies consisting of 
children with mild-to- moderate immunosuppression (mean CD4% of 20% – 25%) 
have reported a prevalence of low HDL-c varying from 30% – 45% [81, 33].  These 
data set lend support to the fact that more advanced HIV disease is associated with a 
higher prevalence of hypo HDL-c, probably due to HIV viral replication causing 
dysregulation of intracellular lipid metabolism in HIV-infected macrophages [82]. 
Hypertriglyceridemia was seen in a higher proportion of children in this study 
(36.4%), in contrast to the Thai pediatric cohort (28%) [81]. A study among ART-
naïve HIV-infected adults from South India also showed a 31% prevalence of 
hypertriglyceridemia [83]. This high regional prevalence of hypertriglyceridemia 
119 
 
among HIV-infected patients may be either due to the advanced stage of the disease 
by the time it is diagnosed or it may be a consequence of diets high in carbohydrates. 
Majority of the children in this study were from families belonging to the lower socio-
economic strata, whose staple foods are largely carbohydrates. The prevalent 
hypertriglyceridemia might be due to a phenomenon known as carbohydrate-induced 
hypertriglyceridemia. This is paradoxical because the increase in dietary carbohydrate 
usually comes at the expense of dietary fat. Thus, when the content of carbohydrates 
in the diet is increased, fat in the diet is reduced, but the content of fat (triglycerides) 
in the blood rises [84].  The dietary intake of fat was however found to be higher in 
girls with high serum TGL levels as compared to girls with normal serum TGL levels. 
The majority of the children received either a Zidovudine or a Stavudine based 
regimen along with lamivudine and one of the NNRTIs (Efavirenz or Nevirapine). In 
our cohort, the dietary intake of iron, folate and calcium were significantly lower than 
the RDA across the different age groups, similar to those shown from other parts of 
the South Asian peninsula [69,85]. Fat intake was almost 100% RDA in children 
>4yrs of age. 
In this cohort, 20% of ART-naïve children showed insulin resistance; much 
lesser than that observed among ART-naïve adults (37%) from this region of the 
country [86]. The discovery of high insulin resistance among ART-naïve children is 
important as it will serve as baseline information for the progression of insulin 
resistance consequent to long term ART use in these children. The HIV proteins Tat, 
Vpr, Vif, Rev, and Nef, as well as the inflammatory cytokines interleukin-2, and 
tumor necrosis factor-α, have been implicated in insulin resistance, loss of lean body 
mass, growth impairment and abnormal serum lipids in ART-naïve patients [87, 88]. 
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The study found an association between high HIV viral load, high TGL and low 
HDL-c levels; stunting and low HDL-c as well as low CRP levels; underweight and 
low insulin resistance among this cohort of ART naïve HIV infected children. 
Treatment with generic fixed dose combinations for children and early 
initiation of ART can go a long way in achieving a sustained clinical, immunologic 
and virologic response. At the end of the first year on ART, more than 70% of the 
children were virologically suppressed with a positive increase in their CD4 cell 
counts. This result was similar to other cohorts of children receiving 
Stavudine/Zidovudine in a first-line ART regimen [89, 90].  
After starting ART, viral load should decrease and CD4 cell count increase.   
However, discordant responses may also occur as seen in this cohort. In these cases 
there may be a delay of 6 months to 1-year before the CD4 cell count starts declining. 
In many national programmes, the response to treatment is monitored by periodic 
measurement of CD4 cell count and not viral load.  With this discordance between 
viral load and CD4 count, an individual may fail virologically, but not be identified as 
such by the common test in the programme, which measures CD4 cells only. As 
immunological criteria do not accurately predict virological failure, a significant 
misclassification of treatment responses occurs, thus delaying the switch to other ART 
formulations [91]. During this period drug resistant viruses may accumulate, 
ultimately leading to treatment failure. Hence there is an urgent need to include viral 
load testing during ART initiation and at periodic intervals for better monitoring for 
treatment response [92].  
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Failure in ART increased among older children and as children reached 10 
months of therapy. These trends may be explained by drug fatigue, pill burden, peer 
pressure at school, or just out of curiosity. 
Not only does antiretroviral treatment improve the immunologic status of an 
individual, it also partially reverses the adverse effects of HIV.  Most ART-naïve 
children experience recovery of both WAZ and HAZ over the 24 months after ART 
initiation, with no significant difference between the types of regimen used [93].  
Catch-up growth  in terms of age-related-height and weight was evident in this grup 
of children after ART initiation. There were significant improvements in all 
anthropometric indices at any given follow-up time-point after first-line ART 
initiation. Similar finding have been reported in other resource-limited settings [93, 
94]. 
In many failures to ART was seen more among children in the older age 
groups and after almost 10 months of therapy. This could be because of either drug 
fatigue or because the children going to school start skipping medicines either due to 
school or peer pressure, pill burden or just out of curiosity. As viral load decreases, 
CD4 cell count increases after start of ART, however discordant responses may also 
occur at times as seen in our cohort. In many national programmes, the response to 
treatment is monitored by periodic measurement of CD4 cell count and not viral load. 
Hence, with this kind of discordance between viral load and CD4 count, an individual 
may fail virologically, and may not be picked up by the commonly used test in the 
programme – CD4 testing. There may be a delay of 6 months to 1 year before the 
CD4 cell count starts declining. As immunological criteria do not accurately predict 
virological failure this results in significant misclassification of treatment responses, 
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thus delaying the switch to other ART [91]. This may result in accumulation of drug 
resistant viruses ultimately leading to treatment failure. Hence, there is an urgent need 
for inclusion of viral load testing in the initiation and monitoring of ART [92].  
Not only does antiretroviral treatment improve the immunologic status of an 
individual but also reverses the adverse effects of HIV to some extent.  Most ART-
naïve children experience recovery of both WAZ and HAZ over the 24 months after 
ART initiation, with no significant difference between the types of regimen used [93].  
Catch-up growth in terms of age-related-height and weight was evident in our cohort 
after ART initiation. There was a significant improvement in all anthropometric 
indices at any follow-up time-point after initiation of first-line ART among the 
children. Similar finding have also been reported from other resource limited settings 
[93, 94].  HAZ was linearly related to immunologic recovery following ART 
initiation in under-five children in Ethiopia [95]. In fact, it has been suggested that 
anthropometric indices could be taken as proxy indicators of immunologic recovery 
for under-five children. After 24 months of ART, though a small proportion of 
children remained stunted and underweight for their age, catch-up growth was evident 
in majority of the children.  
After 24 months of ART, in this cohort, the mean serum HDL-cholesterol 
normalized and the proportion of children with high serum triglycerides reduced 
considerably. This explains the fact that both growth retardation and abnormal serum 
triglycerides in this cohort could have been the result of advanced stage of the HIV 
disease, which was brought under control with the initiation of ART. This also 
emphasizes the fact that early initiation of ART, irrespective of baseline CD4 cell 
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counts in children with HIV infection, has a definite role in the long term morbidity 
and quality of life of these children. 
Significant changes in serum lipid profile occur early in children started on 
first-line ART. Any dyslipidemia, defined as serum triglyceride >130, or LDL-
cholesterol >150, or total cholesterol > 200 mg/dl at 24 months of ART, was seen in 
24% of children in our cohort. Other studies from India have shown a 38% prevalence 
of dyslipidemia among children who received at least 6 months of ART [47]. Though 
this number is small and the mean value of any of the lipid levels within the group 
remained below the abnormal values, it is evident that these children require close 
monitoring for increase in their lipid levels as they continue to take antiretroviral 
medications. The point of solace is that the increase in the cardio protective HDL-c 
was proportionally greater than the increase in TC or TGL. This can also be the result 
of control of the disease with an effective ART as low HDL-c is a marker of disease 
progression. Hence, regular monitoring of lipid levels will help in early identification 
of metabolic complications of ART.  
The prevalence of insulin resistance, as measured by HOMA-IR at baseline or 
in the pre-ART period was low in this group of children; similar to results from 
Thailand and other cohorts of HIV infected children on NNRTI based ART [25, 96]. 
Also the mean serum insulin level in this group (2.2 μU/ml) was lower than the non-
HIV infected control in the community (4.04 μU/ml) [27]. With the continued intake 
of ART, there was a significant increase in the mean serum insulin levels in these 
children, nearing the normal range. Though not statistically significant, 9% of 
children showed HOMA-IR of above normal levels after 24 months of ART. Most of 
the children with higher HOMA-IR belonged to higher age group. Insulin resistance is 
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known to increase during Tanner stages II–IV of puberty, and with increasing age 
[25]. The higher values among the older children in the cohort probably reflected 
pubertal initiation. The children in our cohort were small built and thin during pre-
ART period, with poor immunological and virological indices, all probably as a result 
of untreated HIV infection. Serum insulin levels have also been shown to be 
positively correlated with body mass index and waist-hip ratio [97]. However in our 
group the correlation between body mass index and insulin levels were significantly 
low. Untreated HIV infection is known to be associated with growth failure and 
increased insulin and HOMA IR levels, but catch-up growth occurs with appropriate 
antiviral therapy. With ART, the children in the cohort showed significant 
improvements in all measured growth parameters, suggesting catch-up growth 
significant recovery from baseline stunting. Serum insulin levels also improved, with 
a small proportion showing HOMA-IR also. Therefore, any changes or derangements 
in glucose metabolism were more likely to be attributable to adverse effects of ART 
rather than to poorly controlled HIV infection or stunting.  It has been shown that 
though there is a high prevalence of dyslipidemia and insulin resistance in children on 
ART,  the presence of visually obvious lipoatrophy was associated with elevated 
triglycerides but not with total cholesterol, LDL, HDL, HOMA-IR [25] and efavirenz 
exposure having only transitory effect. 
             Besides factors like stage of the disease and dietary intake, and the type of 
ART regimen, the presence of gene polymorphism and epigenetic factors also 
contribute to changes in serum lipid profile. In this group of children from south India 
those with wild type gene polymorphisms in APOA5 gene, started on a stavudine 
containing regimen showed preponderance to higher levels of total cholesterol and 
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LDL-cholesterol, irrespective of dietary fat intake.  Among children started on 
zidovudine containing regimen, an increase in serum triglyceride was seen in those 
with carrier allele ‘C’ while the presence of wild type polymorphism showed an 
increase in the mean serum total cholesterol levels. Single nucleotide polymorphisms 
of ABCA1, APOA5, APOC3, APOE, and CETP have been shown to contribute to 
plasma triglyceride and HDL-cl levels during antiretroviral therapy exposure [98, 99]. 
Association with APOA5 gene carrying rs3135506 and serum triglyceride levels was 
noticed in patients in Barcelona, with a 9% increase in circulating TG levels 
(p=0.002) and 10% decrease in HDL-c levels (p=0.005) was observed. They also 
found that this association of APOA5 towards dyslipidemia was accompanied by a 
21% decrease of the CD4 T-cell count and a 19% increase in CD8 T-cell count in 
carriers of the rare allele in the APOA5 rs662799 polymorphism [100]. 
Also HIV proteins Tat, Vpr, Vif, Rev, and Nef, as well as inflammatory 
cytokines interleukin-2 and tumor necrosis factor-α have all been implicated for 
insulin resistance, loss of lean body mass, growth impairment and abnormal serum 
lipids in ART-naïve patients [101, 88].   
This study demonstrated a definite role for interaction between gene, type of 
antiretroviral regimen and dietary intake of children in the development of 
dyslipidemia. Though there was no overt increase in the mean serum level of total 
cholesterol or triglycerides after 24 months of ART, there was a trend towards 
increase in the mean values from the pre-ART levels, especially in serum total 
cholesterol and LDL-cholesterol. Also, there was a small proportion of children who 
had a higher than normal range of serum triglycerides after 24 months of ART. This 
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group of children would definitely need periodic close monitoring at regular intervals 
in the subsequent years. 
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SUMMARY AND CONCLUSION 
 
To summarize, as increasing number of HIV infected children receive 
NNRTI-based antiretroviral treatment regimens in India, the morbidity and mortality 
due to HIV is decreasing with a corresponding increase in the longevity of these 
children. Although ART has a great beneficial effect, it also leads to a higher 
incidence of complications including metabolic complications. The incidence and 
patterns of metabolic complications among these children starting ART in India are 
not currently known.  
This study began with the hypothesis that with the long-term use of an ART 
regimen consisting of 2NRTIs + 1NNRTI as per the Indian ART Programme, children 
are prone to develop metabolic complications after two years of continuous ART 
usage by virtue of its very mechanism of action, especially under a specific 
combination of drugs, diet and gene polymorphisms. The objectives of this study were 
two-fold: (1) To determine the incidence of dyslipidemia, insulin resistance (by 
HOMA), and body shape changes (defined by anthropometry) in HIV-infected 
children between the ages 2-12 years, at 24-months after initiating first-line NRTI-
based anti-retroviral treatment regimen and (2) To identify risk factors (both 
nutritional and genetic) associated with the development of lipodystrophy syndrome 
in children between the ages of 2-12 years, also at 24-months after initiating first-line 
NRTI-based anti-retroviral regimen. 
This research was a prospective cohort study of HIV infected children about to 
initiate ART as per the clinical and immunological criteria of NACO guidelines 
(National AIDS Control Organization), at the National Institute for Research in 
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Tuberculosis and the Institute of Child Health and Children’s Hospital, Chennai, 
India. An approximately equal number of males and females in the 2-12 years age 
group were recruited. The study intended to look at various risk factors including diet, 
drugs and, gene polymorphisms in the development of ART induced metabolic 
complications. Children were enrolled to the study with follow-up every 3 months 
after ART initiation. The ART regimen consisted of d4T/ZDV, 3TC and NVP/EFZ 
provided by the government-sponsored clinics at ICH, Chennai. Data on body shape 
(anthropometry) was obtained at intervals of 3 months and data for metabolic change 
(serum lipids and insulin) was obtained at intervals of 6 month for the 24 total months 
of the study period. The study endpoints were the differences between the baseline 
and 12 month measures for the participating children. Two hundred Art naïve children 
were enrolled, ART initiated, and received periodic follow-up for 2 years.  
 
MAIN FINDINGS OF THE STUDY 
(i) Before ART initiation (at ‘0’ month or Baseline) 
 The majority of the HIV-infected children attending ART center in a Southern 
Indian tertiary care hospital presented at late stage of HIV disease leading to 
delay in ART initiation. 
 The majority of these children had low serum HDL-c, about 35% had a high 
serum triglyceride, and a quarter had insulin resistance as measured by 
HOMA-IR even before ART initiation. These measurements provide evidence 
as to the late presentation of the disease. 
 Increased dietary fat intake and low intake of iron, folate and calcium were 
observed in the group.  
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 Associations between underweight and high serum triglycerides, and between 
stunting and insulin resistance in the risk range for metabolic syndrome were 
demonstrated in this group of malnourished, food insecure ART naïve HIV 
infected children.  
 Stunting and wasting were also associated with low levels of HDL-c.  
 
(ii) After ART initiation (at 12 months) 
 Adherence to ART, as recorded by self-reporting and pill counts, was >90% in 
both food secure and insecure households.  
 Nutritional improvement, measured by recovery in age-related height, weight, 
mid-arm circumference and body mass index (i.e., catch-up growth) was seen 
in both the food secure and insecure households.  
 In untreated HIV infected children, (observed via high CD4 cell count) from 
the same socio-economic status and age group, the study observed growth 
failure and insulin resistance after 1-year of follow-up. It therefore follows 
that ART adherence is an important determinant in the nutritional status of 
HIV-infected children.  
 70% of the children were virologically suppressed at the end of 12 months on 
ART.  
 Almost a quarter of these children had virologic failure and developed major 
drug-resistance mutations after 48 weeks on ART.  
 A lack of correlation between Immunologic and virologic failure was noticed.  
 Accumulating mutations for both NRTI and NNRTI group of drugs while on 
treatment were also found. 
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(iii) After ART initiation (at 24 months) 
 Any degree of dyslipidemia (Sr. TC or TGL or LDL-c) was seen in 24% of the 
children on ART. While on ART, the increase in the cardio protective HDL-c 
in serum was proportionally greater than increases in TC or TGL.  
 Long-term follow-up of children on ART showed changes in their lipid profile 
with a higher proportion of the children showing abnormal lipid levels over 
time.  
 Significant changes in serum lipid profile occur early in children started on 
first-line ART, especially when the regimen contains Stavudine.  
 Higher fat intake was associated with high serum triglycerides, especially in 
girls and particularly as age increased. 
 The risk of hypertriglyceridemia was high among children with a carrier allele 
of the APOA5 gene.   
 With improvements in underweight and wasting, development of dyslipidemia 
while on ART can be prevented 
 Specific gene polymorphism, underweight and wasting had a role in the 
development of dyslipidemia, especially in the presence of increased dietary 
fat intake and antiretroviral drugs like Stavudine and (less likely) Zidovudine.  
 
Regular monitoring of lipid levels will help in identifying metabolic 
complications caused by ART earlier. Similarly, periodic plasma HIV-RNA testing 
should be performed to detect treatment failures early. Closer monitoring of 
adherence, viral suppression, drug resistance testing, and a switch to a newer regimen 
will be useful in promoting better outcomes among HIV-infected children. Further 
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long term follow-up of these HIV-infected children will enable assessment the effect 
ART has on lipid profiles, insulin sensitivity, and the growth pattern of CLHIV.  
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CHAPTER 8 
 
 
 
 
 
 
 
 
 
IMPLICATIONS OF THE STUDY 
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IMPLICATIONS OF THE STUDY 
 Early initiation of ART is recommended to avoid disease progression and its 
associated complications among children infected with HIV 
 The lack of correlation between immunologic and virologic failures leads to a 
delay in identifying treatment failures and to the accumulation of mutations for 
both NRTI and NNRTI drugs. These negative effects can be avoided by periodic 
viral load measurements in children on ART.  
 Children on ART with detectable viral loads but no drug resistance mutations 
raise concerns about the way adherence is monitored in the programme. 
 Dyslipidemia and glucose intolerance (insulin resistance) were highly prevalent in 
HIV-infected children in southern India, which suggests an imminent need to 
establish facilities for testing and treatment of metabolic abnormalities among this 
population. 
 Many of the risk factors associated with the development of dyslipidemia and 
insulin resistance are modifiable. Children initiating ART should be advised to 
attempt dietary modification with more intakes of green leafy vegetables, 
carbohydrates and protein. 
  Lipidogenic antiretroviral drugs like stavudine should be avoided. 
 Early initiation of ART and proper selection of diet will not only suppress HIV, 
but will also facilitate catch-up growth through the correction of HIV-induced 
underweight and wasting in children. 
 A good diet can act as double-edged sword. An increased intake of carbohydrates 
will not only correct the wasting and underweight, but can also increase the serum 
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triglyceride levels in susceptible individuals. The negative effect can be partly 
mitigated by paying attention to the type of ART initiated. 
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